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ABSTRACT 
SARAH GAIL BRADSHAW. Fli-l in B Cell Proliferation and Systemic Lupus 
Erythematosus. (Under the direction of GARY GILKESON). 
PBMC from patients with SLE and splenic lymphocytes from murine models of SLE 
demonstrate increased expression of the ETS transcription factor Fli-l. Transgenic 
overexpression of Fli-l in normal mice leads to SLE-like disease. These findings suggest 
investigation of the role of Fli-l in SLE may elucidate etiology of the disease and potential 
therapies. The MRLI/pr mouse is a model of SLE exhibiting increased lymphocytic 
expression of Fli-l. Reduction of Fli-l expression by heterozygousity at the Fli-J locus 
(Fli-J+1-) results in decreased auto- and alloantibodies, proteinuria, and renal pathology; and 
drastically decreased mortality. Disruption of the C-terminal transactivation domain (Fli-
JI1CTAlI1CTA) reduces the ability of Fli-l to activate target genes, but does not affect 
expression or DNA-binding. Effect of Fli-l deficiency on B cell proliferation was 
evaluated in three models - Fli-l+l- MRLI/pr, Fli-J+I- C57BL/6, and Fli_l~CTAlI1CTA 
C57BL/6 mice. Proliferative responses of naIve B cells from Fli-l-deficient mice to anti-
IgM, a combination of PM A and ionomycin, CpO DNA, or LPS were significantly reduced 
compared to those of Fli-l-wild-type mice of similar strain. Expression of corresponding 
mitogen receptors was also evaluated. Surface expression of BCR components IgM and 
Iga, TLR4, and TLR9, and intracellular expression of TLR9 was only slightly and 
inconsistently reduced in naIve B cells of Fli-l-deficient mice compared to Fli-l-wild-type 
mice of similar strain. Transcript expression of several TLR and BCR signaling-related 
genes was also evaluated. IL12a transcripts were upregulated in Fli-l-deficient MRL/lpr B 
cells. Transcription of the gene encoding the transcription factor NF AT, a known activator 
xu 
of proliferation, was downregulated in Fli-I-deficient MRLllpr B cells. The results of 
these studies clearly demonstrate that Fli-l deficiency affects B cell proliferative responses 
to mitogens, independent of BeR and TLR expression. Also, IL12a and NFAT were 
identified as potentially regulated by Fli-l. Based on published evidence, the differential 
expression of these genes may dampen proliferative responses of B cells to mitogens. 
Ultimately, this may be a mechanism by which overexpression ofFli-1 contributes to B cell 





Systemic lupus erythematosus: Incidence, etiology. and mortality 
Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease 
characterized by numerous immunological abnormalities. Prevalence of SLE in the United 
States is unclear, due to inadequate population sampling and complexity of diagnosis. In 
1996, the most recent formal study addressing prevalence of SLE estimated 24 out of 
100,000 Americans suffer from the disease (1). Lupus Foundation of America currently 
estimates that over a million are affected (2). Incidence and prevalence of the disease is 
estimated to be higher, however, in Europe and Australia (3). It has been firmly established 
that world-wide, the frequency of SLE among females and African-Americans IS 
significantly higher than among males and Caucasians, respectively (4, 5). 
Genetics. The precise etiology of this disease remains to be determined and appears to 
be multifaceted. Evidence from many studies undeniably attributes SLE, a least partially, 
to genetic susceptibility, which is supported by the aforementioned gender and racial 
disparities. However, genetic heterogeneity, a single phenotype resulting from multiple 
genetic combinations, makes predicting SLE susceptibility problematic. Demonstrating 
this concept, some susceptibility loci uncovered in BXSB mice differ from those 
established in other murine models of SLE, including NZBINZW and MRLllpr mice (6). 
Epistatic gene interactions, in which the phenotype of a genotype is influenced by a 
genotype at another locus~ further compounding determination of genetic susceptibility to 
SLE. For example, combining Slei, an SLE susceptibility locus derived from the 
NZM2410 mouse strain, with yaa, a susceptibility gene derived from the BXSB strain, 
results in severe autoimmunity, while their individual effects, in absence of the other, are 
2 
nonfatal (7). Epistasis can also have beneficial effects on SLE. In the NZW mouse strain, 
the combination of four identified protective loci suppress the effects of the three 
susceptibility loci it carries (8). Individual genes within susceptibility loci have been 
identified, and subject to linkage analysis. Polymorphisms of a diverse collection of genes, 
including Fc 'Y receptors Ila, lIb, and IlIa; protein tyrosine phosphatase N22, leukocyte 
tyrosine kinase, interleukins 6, 8, and 10; p53, tumor necrosis factors u and ~, monocyte 
chemoattractant protein 1, human leukocyte antigens, epidermal growth factor receptor, 
interferon gamma receptors, estrogen receptor u, endothelial nitric oxide synthase, DNase 
1, CD154, cytotoxic T lymphocyte antigen 4, c-reactive protein, programmed cell death 1, 
Bcl-2, Clq, interleukin 1 receptor agonist, Fas, mannose binding lectin, e-selectin, 
osteopontin, and prolactin, have been reported to be associated with development of SLE 
itself or characteristics of SLE, such as particular autoantibodies or nephritis (9-38). 
Epigenetics. Current research also indicates that genetics alone is not sufficient to 
induce disease. In a study of monozygotic twin pairs in which at least one twin had SLE, 
only 24% of the pairs both had the disease (39). The same study also revealed that 20/0 of 
dizygotic twin pairs were concordant. The increased concordance found in identical twins 
compared to nonidentical twins supports the presumed genetic etiology for SLE, but also 
clearly suggests that nongenetic factors playa significant role. Alterations in expression of 
genes, without modification of their sequence, is a phenomenon known as epigenetics. 
Epigenetic changes include DNA methylation and posttranslational histone modifications. 
For example, DNA of T cells from SLE patients exhibits less methylation than T cell DNA 
of healthy individuals and treatment with histone deacetylase inhibitors can reverse some T 
cell abnormalities and renal disease associated with murine SLE (40-42). 
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Stochastic events. It is also believed that onset of disease can be triggered by a random 
immunological event, and the consequences are dictated by genetic predilection. A study 
in which the incidence of lupus-prone mice developing a particular autoantibody was 
examined supports this theory (43). The study concluded that development of the 
autoantibody was not influenced by environment, genetics, parentage, or sex, suggesting 
stochastic events are likely involved. 
Environment. Interestingly, 5% of dogs owned by SLE patients also have SLE, while 
canine SLE is absent among those with non-SLE owners; compelling evidence that 
development of SLE is dependent to some degree on environmental dynamics (44). Also, 
68% of people living with, but not related to, an SLE patient develop autoantibodies, 
whereas only 23% of people who are consanguineous relatives of, but do not live with, a 
patient develop autoantibodies (45). Suspected environmental contributory factors include 
Epstein-Barr or parvovirus infection and Hepatitis B vaccine (46-48). Molecular mimicry 
has also been considered a possible contributor to the development of autoantibodies. One 
study demonstrated the ability of antipneumoccocal antibodies, produced by vaccinated 
patients, to bind self-antigen (49). Exposure to pristane, dust containing high levels of 
silica, or well water containing trichloroethylene, trichloroethane, and inorganic chromium, 
have also been connected to development ofSLE (50-52). 
Drugs. Drug-induced SLE is associated with dozens of medications with diverse 
functions, including treatment of seizures, infections, arrhythmias, hypertension, and 
honnonal imbalances. Drug-induced SLE has also been associated with therapeutic 
administration of cytokines (53). Most of the mechanisms underlying drug-induced SLE 
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remain to be determined, but some cases can be attributed to differential metabolism. For 
example, slow acetylation seems to be the cause of hydralazine-induced SLE (54). 
Lifestyle. Aspects of lifestyle, such as diet and tobacco use, are suspected to contribute 
to development of SLE. The amino acid L-canavanine, a component of alfalfa, has been 
connected to simian SLE (55). Current smokers have a significantly increased risk of 
developing the disease, while former smokers do not (56). Even low frequency noise has 
been shown to enhance SLE development in susceptible mice (57). 
Therapy. Due to the vast heterogeneity of the disease, treatment can be difficult. 
Typical therapy includes administration of an immunosuppressant, like mycophenolate 
mofetil (MMF), the folic acid metabolism inhibitor methotrexate (MTX), and rituximab, a 
cytotoxic monoclonal antibody which targets B cells via CD20 (58-61). Several promising 
novel treatments specifically targeting molecular mechanisms of the disease are under 
investigation, though none have yet proven to be successful replacements for current 
therapies (62, 63). 
Death. Morbidity and Mortality Weekly reported in 2002 that the number of SLE-
related deaths had risen 33% between 1979 and 1998, though whether this figure reflects 
improved diagnostic abilities is in question (64). While 76% of patients survive at least 15 
years following diagnosis, hospitalizations are lengthy and expensive (65, 66). In surveys 
assessing quality of life, the majority of SLE patients reported frequent pain or fatigue, and 
roughly half reported anxiety, depression, or difficulty with usual activities (67). Leading 
causes of death in SLE patients are infection, circulatory disease, and renal failure (68). A 
slightly increased incidence of cancers, particularly lymphoma and lung cancer, also 
contribute to mortality. Patients who are female, African-American, or under the age of 40 
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are most at risk for SLE sequelae-related death. However, risk of female mortality is 
reduced in those with low levels of female sex hormones (69). 
B cell hyperactivity in SLE 
The immunological abnormalities observed in SLE can be categorized into three types: 
production of pathogenic autoantibodies, impaired ability to process and eliminate immune 
complexes, and lack of regulation regarding T and B lymphocyte functions. Because these 
abnormalities span much of the immune system and, to a large extent, are interrelated, it is 
difficult to determine which aberrations are causing disease, and which are effects of the 
causal events. It is certain, however, that B cells are major players in the induction of SLE. 
Of course, one of the primary roles for B cells in autoimmunity is the production of 
autoantibodies. MRLllpr mice lacking B cells do not develop nephritis, partially due to 
lack of autoantibodies and immune complex deposition in the kidney (70). SLE patients 
have 1.5 to 4-fold more IgG- and IgM- secreting cells than healthy individuals, but B cell 
functions other than antibody production contribute to autoimmunity (71). Lupus-prone 
mice with B cells that express immunoglobulin, but are unable to secrete it, still develop 
nephritis, though less severely (72). Other B cell mechanisms of pathogenicity may 
include cytokine production and antigen presentation. 
B cell hyperactivity is a classic characteristic of SLE. Patients demonstrate significantly 
higher numbers of activated B cells in the peripheral blood and bone marrow than normal 
individuals (73). Upon in vitro exposure to bacterial antigens, B cells from SLE patients 
proliferate at a significantly higher rate than B cells from nonnal individuals (74). It is 
thought that B cells from SLE patients behave similarly in vivo, upon exposure to self and 
other antigens. Accordingly, B cells from SLE patients also demonstrate abnonnal 
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signaling events in response to B cell receptor (BCR) engagement, including elevation of 
phosphorylated proteins and calcium influx (75). Increased calcium influx is due in part to 
inadequate inhibition through FcyR lIb (76). 
Polymorphisms. Several mechanisms leading to the B cell hyperactivity associated with 
SLE have been investigated. A polymorphism in the kinase domain of leukocyte tyrosine 
kinase (L TK), an intracellular signaling protein predominantly expressed in B cells, was 
more frequently observed in SLE patients than in healthy individuals (13). When this 
polymorphism was studied in NZBINZW mice, evidence suggested that it leads to 
hyperactivity of the phosphatidylinositol 3-kinase (P13K) pathway, whose signaling events 
lead to cellular proliferation. Another polymorphism thought to contribute to B cell 
hyperactivity is that of CD72, a B cell surface molecule known to regulate BCR signaling 
(77). In a study that compared CD72 transcript sequences from SLE patients to those of 
healthy individuals, 96% of transcripts from patients exhibited mutations (78). Of those 
mutations, 41 % were located in a region known to suppress BCR signaling. Given that this 
study also found CD72 to be underexpressed in SLE patients, it is proposed that B cell 
hyperactivity is promoted by diminished BCR signaling regulation through CD72. 
BAFF. BAFF-R, and TAeL Another suggested mechanism of B cell hyperactivity in 
SLE is the overexpression ofB cell activating factor (BAFF) (known also as BLyS, TALL-
1, THANK, TNFSF20, TNFSF13 and zTNF4), which plays an important role in B cell 
survival. Transgenic overexpression of BAFF in nonautoimmune mice led to SLE-like 
disease featuring hypergammaglobulinemia, autoantibodies, immune-complex deposition 
in the kidney, and B cell hyperplasia (79). Of human patients, 23% have elevated serum 
BAFF levels (80). Expression of two receptors for BAFF, B cell activating factor receptor 
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(BAFF .. R) and transmembrane activator and cyclophilin ligand interactor (TACI), is also 
significantly increased in SLE patients (81). BAFF knockout mice display severe defects in 
B cell development and proliferation (82). Interestingly, TACI seems to have a negative 
regulatory role in B cell homeostasis, as knockout mice develop a lupus-like disease and 
rAeI agonists inhibit B cell proliferation (83). Both receptors are expressed on the surface 
of B cells. Expression of BAFF and both receptors correlates to disease activity, making 
them attractive targets for new therapies. 
Lyn. Decreased expression of Lyn kinase in SLE patients has also been identified as a 
possible source of B cell hyperactivity (84). Lyn overexpression has been found in some 
SLE patients (85). Adequate Lyn activity seems to be critical for maintaining B cell 
tolerance, through its regulatory role in BCR signaling, B cell proliferation, and apoptosis 
(86). Interestingly, mice possessing a mutated, hyperactive Lyn and mice lacking Lyn 
demonstrate the same phenotype - B cell hyperactivity, hypergammaglobulinemia, 
autoantibody production, and immune complex mediated nephritis (87-90). Defective 
regulation of BCR signaling through Fcy receptor lib is suspected to contribute to the Lyn 
knockout phenotype (89). 
TLR9 and CpG DNA. Toll-like receptor 9 (TLR9) is a member of a group of integral 
membrane proteins whose function is to recognize pathogen associated molecular patterns 
(PAMPs) and initiate innate immune responses (91). Bacterial CpG DNA is the ligand 
which interacts with TLR9 (92). Interestingly both B cell expression of TLR9 and 
circulating DNA fragments containing CpG motifs are increased in SLE patients (93, 94). 
The accumulation of these CpG-containing fragments is thought to be a consequence of the 
ineffective clearance of apoptotic debris which is characteristic of SLE (95). B cells of 
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lupus ... prone mIce have a reportedly abnonnal response to CpG DNA in vitro -
overproduction of interleukin 10 (IL 10) and underproduction of interleukin 12 (IL 12) and 6 
(IL6), effects of which are suggested to contribute to disease (96). Surprisingly, absence of 
TLR9 in lupus-prone mice exacerbates disease, leaving the role of TLR9 in SLE 
development ambiguous (97). 
CD40 ligand. B cells from 30% of SLE patients exhibit elevated expression of CD 154 
(CD40 ligand) (98). When expressed on T cells, CD154 interacts with CD40 expressed on 
B cells and induces immunoglobulin production, proliferation, and isotype switching (99). 
The function of CD154 expressed on B cells is unknown, though roles in homotypic 
activation and autoimmunity have been suggested (100). 
Telomerase. During cellular division, telomerase, a nuclear enzyme that adds 
nucleotides to the ends of chromosomes, is activated to prevent apoptosis induced by 
telomeric shortening (101). Telomerase activity is significantly increased in SLE patients 
with active disease, when B cell hyperplasia is occurring (102). It is thought that this is 
another mechanism responsible for exaggerated B cell proliferation and longevity 
associated with SLE. 
Given the implicit role for B cells in the development of SLE, these and other 
abnormalities found in SLE B cells are worthy of thorough investigation. 
Spontaneous murine models o(SLE 
There are 26 murine models of SLE available through The Jackson Laboratory, a major 
US distributor of mice intended for biomedical research purposes (103). Such a variety of 
models reflects the diversity of human SLE. Among available mouse models, some 
develop disease as the result of a gene knockout, or addition of a transgene (104, 105). The 
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merits of these models include ability to investigate individual aspects of SLE and 
susceptibility genes, but they provide limited insight into complete disease. Inducible 
models, in which stimulation of immune responses and exposure to auto or alloantigens 
triggers disease onset, are also used (106-109). These models provide information 
pertaining to environmental influences, but, similarly to knockout and transgenic models, 
do not address the heterogeneity of SLE seen in humans. The remainder - the NZBINZW 
Fl (BWFl), NZM2410, NZM2328, MRL/q,r, and BXSB/yaa strains - develop SLE 
spontaneously, most reflecting human disease. While human and murine immune systems 
are not identical, spontaneous models of SLE offer a level of complexity comparable to that 
which we face and find so challenging in human disease (110). In general, all the 
spontaneous models generate autoantibodies and develop glomerulonephritis and exhibit 
female bias, similar to human SLE (111, 112). The exception is the BXSB/yaa strain, in 
which primarily males are affected by SLE as a result of the mutant gene residing in the Y 
chromosome (113). All of these strains demonstrate B cell hyperactivity (114, 115). 
The NZBINZW F1 strain is credited as the first murine model of SLE (116). In addition 
to autoantibody and glomerulonephritis development, this model demonstrates central 
nervous system (eNS) involvement (117). The NZM241 0 and NZM2328 strain were both 
derived from the NZBINZW Fl strain. The NZM2410 strain possesses a combination of 
susceptibility loci that allowed for retention of disease characteristics, but higher 
penetrance and earlier onset (118). Gender bias, however, is lost in this strain. The 
NZM2328 strain possesses an alternative combination of susceptibility loci, even higher 
penetrance, and retains female predominance (119). Given human genetic heterogeneity, 
models demonstrating varied combinations of susceptibility loci are quite informative. 
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The MRLllpr strain is perhaps the most complete model of SLE with 
glomerulonephritis, as it develops more specificities of autoantibodies, arthritis, vascular 
disease, skin lesions, and eNS damage (111, 120). These mice are homozygous for a 
mutation of the Tnfrsf6 gene which encodes the Fas ligand protein, resulting in 
lymphoproliferation. Autoantibody levels are highest, and disease develops most rapidly in 
the MRL/lpr strain (121). Onset of disease typically occurs at about 8 weeks of age and 
death at about 20 weeks of age (122). Analysis of MRLllpr B cells revealed elevated 
numbers of immunoglobulin-secreting cells, activated and/or proliferating cells, and 
mitogen-responsive cells (111). 
The C57BL/6 mouse strain is the most commonly utilized laboratory animal. These 
mice exhibit resistance to some bacterial, fungal, and parasitic infections, and susceptibility 
to others (123-130). However, this strain may serve as a suitable control to compare 
MRLllpr mice to, as they are immunologically well-understood and are not genetically 
susceptible to autoimmune disease. As C57BL/6 mice are conducive to genetic 
manipulation, it is the background on which most transgenic and knockout models are 
developed, including the Fli-l knockout (discussed below). 
Fli-l. an ETS transcription {actor 
Friend leukemia insertion site 1 (Fli-l) was first characterized as a DNA-binding protein 
capable of transcriptional activation (131-133). Based on the high homology of its DNA 
binding domain with that of Ets-l, and the central GGAA motif of the sequence to which it 
binds, Fli-l is classified as a member of the ETS family of transcription factors (134). 
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Regulation ofFli-l expression and activity 
A nwnber of mechanisms regulating Fli-l expression and activity are known. In the 
case of Fli-l and other transcription factor-related diseases, targeting these mechanisms 
offers exciting potential for therapeutic development. Regulation of Fli -1 expression in 
relation to SLE development is currently under investigation (135). In a recent study 
involving lupus-prone mice, an inverse correlation between the length of a microsatellite 
located near the Fli-l promoter and the activity of the promoter in a T cell line was 
reported (136). Though such a mechanism of regulation has not yet been described, 
microsatellite polymorphisms potentially contribute to regulation of Fli-l expreSSIon, as 
well as expression of other genes. 
Activation. The most obvious mechanism of Fli-l expression regulation is the activation 
of transcription by transcription factors. The promoter region of the Fli-l gene, which is 
highly conserved in mouse and human, has been examined closely, and several potential 
regulatory regions have been identified (137, 138). These include binding sites for GATA, 
ETS, and AP transcription factors as well as GC rich and GA-repeating regions (136, 138). 
It is thought that a 5' untranslated region of Fli-l also regulates expression, because this 
region is conserved in mouse and human genes (137). Endothelial and erythroleukemia 
cell studies indicate that the ETS-binding sites in the Fli-l promoter are potentially used by 
Ets-l, Spi-l, and Fli-l itself to activate transcription (139-141). In vitro T cell studies have 
also provided evidence that Elf-l and Tel activate Fli-l transcription through these sites 
(136). There are also three potential STAT-binding sites present in the Fli-l promoter and 
IL6 upregulates Fli-l expression via STAT3 (136, 142). However, mutation of two STAT-
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binding sites increases in vitro promoter activity in T cells, suggesting that S TAT-mediated 
activation or repression ofFli-l expression is cell type dependent (136). 
Alternative exons. Alternative exons have been identified in both mouse and human Fli-
1 (143). Because the translated proteins differ by only a few amino acids, they are thought 
to have identical function. It is suggested that having multiple promoter regions plays a 
role in regulating Fli-1 expression in different cell types. Interestingly, the overlapping 
nature of two upstream open reading frames, which translate to two isofonns of Fli-1, is 
such that termination of translation initiates translation both upstream and downstream 
(144). 
Epigenetics. Expression ofFli-1 is also regulated by epigenetic means. Fli-l expression 
was found to be absent or reduced in fibroblasts isolated from skin affected by scleroderma, 
due in part to methylation of the Fli-J promoter inhibiting transcription (145). Like SLE, 
scleroderma is an autoimmune disease featuring hyperreactive B cells and production of 
autoantibodies (146). 
Inhibition. In seeming contradiction to the previously mentioned report of Tel 
activating Fli-l transcription, Tel binds to the Fli-l protein and inhibits its transcriptional 
activity (147). The fusion protein Tel-AML-l cannot properly bind Fli-1 to regulate its 
activity, and the resulting overexpression of Fli-1 target genes contributes to development 
of leukemia (148). Another protein that inhibits Fli-1 activity by direct binding is PIASxu, 
a protein known to enhance sumoylation of Fli-l, though this is not the mechanism of 
inhibition (149). Also, the retinoic acid receptor has demonstrated ability to repress the 
ability ofFli-l to activate transcription, though it does not directly bind (150). 
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Posttranslational. Mechanisms of posttranslational regulation of Fli-l are unknown, 
though it has been reported that treatment of myeloid cells with granulocyte colony 
stimulating factor (G-CSF) results in extended half-life of the Fli-l protein (151). 
Fli-l and regulation of transcription 
The FH-l gene, located on mouse chromosome 9 and human chromosome 11, possesses 
a 3' ETS domain, like all ETS factors, and an additional 5' domain which translate to 
DNA-binding domains in the Fli-l protein (137, 152). Fli-l is known to regulate 
expression of a diverse collection of genes through transcriptional activation (Table 1). 
Table 1. Genes activated by Fli-1, the proteins they encode, and the processes they influence. 
Process Gene Protein Ref 
C-MPL thrombopoietin receptor 153-155 
megakaryopo ies is GPlba, GPllb, megakaryocyte membrane glycoproteins 153,156-158 
GPVI, GPIX 
Bel2 antiapoptotic protein Bcl2 159, 160 
cell cycle 
Egrl transcription factor early growth response protein 161 
GADDl53 enhancer-binding protein GADD 153 162 
MDM2 oncoprotein mouse double minute 2 163 
vasculogenesis 
Hmoxl human heme oxygenase enzyme 164, 165 
Tne extracellular matrix protein tenascin-C 166 
immunoglobulin 
Dntt terminal deoxynucleotidyltransferase 167 
~gh Ig heavy chain 168 expression/rearrangement 
Mb-l Iga 169 
Eos47 erythroid membrane glycoprotein 170 
Galal transcription factor GAT A-I 171, 172 
miscellaneous Kr12-8 epithelial keratin endoA 173 
Lmo2 cofactor Lim domain only 2 174 
Pld2 signal transducer phospholi2ase D2 175 
An 11;22 chromosomal translocation is known to produce an EWS-Flil fusion protein 
whose transcriptional activation activity results in Ewing sarcoma (176). The Fli-l portion 
of the protein is necessary for DNA-binding, while the EWS portion is responsible for 
transcriptional activation (177). Because the fusion protein retains the DNA-binding 
specificity of Fli-l, EWS-Flil aberrantly regulates Fli-l targets genes (178). As seen in 
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Table 1, Fli -1 activates several genes involved in the cell cycle which play key rolls in 
. . 
carcInogeneSIS. 
The transcriptional regulation T bl 2 G a e . enes represse db FI' 1 d h h d )y I- an t e proteIns t ey enco e, 
Gene Protein Ref 
Coil extracellular matrix protein collagen 179 
Ctgf connective tissue growth factor 180 
activity of Fli -1 is not limited to 
activation. Fli -1 represses 
Mmp] matrix metalloproteinase 1 181 
Pkd] membrane protein polycystin-l 182 
Rb tumor suppressor retinoblastoma protein 183 
transcription of a number of genes with products as diverse as those which Fli -1 activates 
(Table 2). 
The promoter of Lyl1 (lymphoblastic leukemia derived sequence 1), a gene necessary 
for hematopoietic stem cell function, and both the enhancer and promoter of Eng, a gene 
encoding the accessory transforming growth factor ~ (TGF~) receptor endoglin, are bound 
in vivo by Fli-l, but whether FH-l binding activates or represses transcription remains to be 
determined (184, 185). The promoter of the human telomerase gene, hTERT, contains two 
Ets-binding sites - one which acts as a positive regulator and the other, a negative 
regulator. Ability of Fli-l to bind this promoter in vitro has been demonstrated, although 
its effect on transcription has not been reported (186). 
Whether Fli-l acts as an activator or repressor of transcription may be cell specific. 
Though Fli-l activates GATA-1 transcription in COS and He La cells, it has been shown to 
suppress GATA -1 transcription in an erythroleukemia cell line to inhibit erythroid 
differentiation (187). 
Fli-1 deficiency 
In efforts to evaluate functions of Fli -1, specifically those involved in hematopoietic 
differentiation and lineage selection, mice possessing targeted disruption of murine Fli-1 
were developed (188). While heterozygotes display normal phenotypes, all Fli-1·/· 
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embryos suffer neural tube hemorrhage and die by 12.5 days of gestation. Evidence 
suggests that death is caused by a combination of mechanisms - the dysregulation of genes 
encoding extracellular matrix proteins that contribute to vascular integrity, as well as those 
that encode genes related to megakaryocyte development and function. In fact, embryos 
lacking FH-l demonstrate a complete absence ofmegakaryocytes (188). 
Interestingly, humans bearing a deleted segment of chromosome 11 in which the Fli-l 
locus resides suffer Jacobsen or Paris-Trousseau dysmegakaryopoiesis and 
thrombocytopenia (189-192). A significant number of bone marrow-derived 
megakaryocytes from these patients die via activation, lysis, or apoptosis at various stages 
of maturity. It is thought that of the pair, the chromosome 11 bearing the deletion is active 
in megakaryocytes that exhibit premature death, but inactive in those that survive and 
mature normally. 
Studies in which Fli-l is deleted have revealed the importance of Fli-l activity in 
differentiation of all blood cell lineages. Chimeric mice possessing both Fli-l-null and Fli-
l-heterozygous cells exhibit reduction of granulocyte, monocyte, and natural killer cells 
populations (193). Development of mice homozygous for a mutated form of Fli-l resulted 
in decreased thymocyte populations (194). Increased apoptosis was ruled out as a 
mechanism for this phenotype, suggesting that Fli-l may influence T cell progenitor 
maturation or migration to the thymus. Mice with a disrupted Fli-l functional domain, 
tenned Fli_l f1CTAI!).cTA, produce a truncated Fli-l protein, lacking the carboxy-terminus 
transactivation domain, but are viable (unpublished data). This truncated Fli-l exhibits 
50% less transactivation activity compared to native Fli-l (132). Fli-l !)'CTAI!)'CTA mice 
exhibit reduced numbers of total splenic B cells, as well as reduced activated, marginal 
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zone, and follicular B cells (unpublished data). This model is useful because the similarity 
of many ETS binding sites often allows ETS factors to substitute for each other. Erg-3 has 
a DNA-binding sequence that is 98% homologous to that of Fli-I. In the case of JgH 
regulation, Erg-3 and Fli-l bind the enhancer with seemingly equal affinity and activate it 
with equal efficiency (168). In the Fli-J ~CTAI~CTA model, Fli-l retains the ability to bind its 
target genes, but has limited ability to initiate transcription, thereby minimizing the 
possibility of other ETS factors regulating Fli-I target genes. 
Fli-l in murine and human SLE 
In an effort to evaluate the function of Fli -1, similar to deletion studies, transgenic mice 
that overexpress Fli-l were developed (195). Outbred COl mice were used in this study, a 
strain not previously known to be susceptible to development of autoimmune disease. Of 
the tissues examined for Fli-l expression, the highest levels were found in the thymus and 
spleen, the primary reservoirs for lymphocytes. As the transgenic mice aged they began to 
display proteinuria, a typical indication of renal dysfunction, developed chronic renal 
disease characterized by glomerulonephritis, and died prematurely due to renal failure. The 
phenotype displayed by transgenic mice overexpressing Fli-l is remarkably similar to that 
of murine models of spontaneous SLE. 
A number of B cell-related defects are included in the phenotype of Fli-l transgenic 
mice. Strikingly elevated populations of B cells in the spleen and lymph nodes suggest B 
cell hyperplasia, which is supported by the presence of hypergammaglobulinemia. 
Populations of potentially autoreactive CD5+ B cells were also elevated. Anti-DNA and 
anti-nuclear antibodies were detected in the serum. B cells demonstrated hyperreactivity to 
17 
proliferative stimuli and prolonged survival. Together, these finding are consistent with 
features observed in humans and mice affected by SLE. 
Evaluation of naturally occurring Fli-l expression in NZBINZW F 1 mice revealed 
elevated Fli-l RNA levels in splenic lymphocytes (196). Splenic overexpression of Fli-l 
protein has also been demonstrated in MRLllpr mice (197). To assess the effects of Fli-l 
in this model, Fli-l expression was reduced 50% by disruption of one Fli-l allele, 
generating a Fli-I+I- genotype. Evaluation of disease progression in heterozygotes revealed 
reduced anti-dsDNA and anti-glomerular antigen autoantibodies in the serum, drastically 
reduced proteinuria, reduced renal pathology, reduced production of the inflammatory 
chemokine MCP-l, and strikingly extended survival. Taken together, these findings 
indicate that reduction of Fli -1 has a profound impact on progression of SLE, with 
predominant effects within the lymphocytic compartment. 
Fli-l was found to be expressed at a higher level in peripheral blood mononuclear cells 
(PBMC) of SLE patients than in PMBC of normal individuals (196). Expression of Fli-l 
also correlated with disease activity. Higher levels of Fli-l were found in patients 
categorized as having "very active" disease than in patients with "moderately active" or 
"inactive" disease. There was no apparent correlation between Fli-l expression and 
duration of disease, clinical characteristics, or response to treatment. This information 
suggests Fli-l overexpression may precede and influence development ofSLE. 
Significance 
The literature concerrung Fli-l and SLE clearly link this transcription factor to 
manifestations of disease, as well as to regulation of B cell function. The probability that 
Fli-l has a substantial impact on murine SLE development and/or progression via its 
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influence on B cell activities is worthy of investigation. Furthennore, findings related to 
such potential mechanisms of disease are translatable to future human studies. 
Understanding the role of Fli-l in murine SLE B cells may also lead to novel methods of 
treatment, targeting Fli-l itself or, more likely, its pertinent target genes. 
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Chapter 2 
EFFECT OF FLI-I DEFICIENCY ON B CELL PROLIFERATION 
Aims and Rationale 
Aim 1 a: To assess the effect ofFli-l deficiency on B cell proliferation in SLE 
Transgenic mice that overexpress Fli-l exhibit B cell hyperplasia, evident by increased 
numbers of mature B cells in both lymph nodes and spleens (195). Transgenic B cells also 
demonstrate exaggerated proliferative responses to lipopolysaccharide (LPS) and anti-IgM. 
Also, Fli-l-heterozygous mice demonstrated lower percentages of B cells in the spleen 
(197). Therefore, experimental support for the theory that reducing Fli-l expression to a 
level below baseline would reduce B cell proliferative response to mitogens was sought. It 
was hypothesized that impaired B cell proliferation contributes to the decreased production 
of immunoglobulins, including those that are autore active , observed in Fli-l+l - MRLI/pr 
mice, and thus contributes to the decreased severity of their disease and extended survival 
(197). 
Aim 1 b: To assess the effect ofFli-l deficiency on B cell proliferation in normal immunity 
It was suspected that effects of Fli -1 deficiency on B cell proliferation are not confined 
to the context of SLE or autoimmunity, and Fli-l activity is integral to the process in 
normal immunity. It was hypothesized that B cells from Fli-l+l- and Fli_l/!,.cTAJ/!,.cTA 
C57BL/6 mice suffer proliferative impairment similar to that of B cells from Fli-l+l-
MRLllpr mice. Furthermore, comparing effects of Fli-l deficiency in a normal or 
autoimmune environment had potential to expand current understanding of molecular 
defects associates with SLE. 
Aim 1 c: To determine temporal role ofFli-l in SLE progression via B cell proliferation 
In Fli-l transgenic mice, overexpression of Fli-l preceded the manifestation of disease 
(195). Therefore, seeing effects of reduced Fli-l expression early in the progression of 
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disease in MRLllpr mice was anticipated. Examination of B cells collected at various ages 
representing different stages of disease was intended to detennine the contribution of Fli-l 
to disease-initiating or secondary events. 
Because proliferation may be initiated through multiple signaling pathways, 
investigation of responses to several mitogens was deemed necessary to identify the 
mechanistic role of Fli-l in B cell proliferation. Observed disruption of a single signaling 
pathway would indicate that Fli-1 affects early events in the process, whereas disruption of 
multiple pathways would indicate that Fli-1 affects downstream events which are common 
to the affected pathways. 
Background 
Induction ofproliferation by BCR crosslinking 
A common means of inducing proliferation of B cells is by antigen receptor ligation 
(198). BCR cross-linking via anti-IgM activates tyrosine kinases (PTK), which facilitate 
phosolipase C activation and phosphatidylinositol turnover, to prompt Ca2+ influx and 
activation of protein kinase C (PKC) via generation of diacylglycerol (199-202). Ca2+ is an 
important activating cofactor for many enzymes, and its mobilization is driven in part by 
BCR-associated Lyn (203, 204). Other proteins involved in the BCR-activated mitogen-
activated protein kinase (MAPK) pathway include Ras, Rafl, protein kinase C-associated 
kinase (PKK), MEK, and ERK1/2 (205-207). Immunoglobulin-binding protein 1 (IGBP1), 
IkappaB kinase p (IKKP), Ras guanyl nucleotide releasing protein 1 and 3 (RasGRPl/3), 
and c-Rel knockout and FynlLyn double knockout models all demonstrate defective B cell 
proliferation in response to BCR ligation, though the precise roles of these proteins in the 
process is not known (208-213). Induction of nuclear factor K B (NFKB) is a critical step in 
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the response to BCR crosslinking (214). The quality of the proliferative response to anti-
IgM antibodies can vary according to specificity, avidity, and concentration (215, 216). 
Induction ofproliferation by LPS 
LPS-binding of coreceptors CD14 and Toll-like receptor 4 (TLR4) stimulates 
proliferation, but does not initially activate tyrosine kinases, whereas anti-IgM does so 
within minutes (202, 217, 218). PTK and PKC activation occurs slowly and peaks at 72 
hours after LPS stimulation (219, 220). Unlike BCR crosslinking, LPS does not induce 
phosphatidylinositol turnover, or calcium ion mobilization. The cascade of signaling 
proteins activated by ligation of TLR4 includes MyD88, IRAK, TRAF6, protein kinase A 
(PKA), MEK1/2, ERK, p38, and AP-1 (221-223). Knockout and mutant models suggest 
important roles for surface proteins such as radioprotective 105, MD-1, and MD-2; 
signaling proteins such as Smad7, phosphoinositide 3-kinase (PI3K), IKB kinase ~ (IKK~), 
caspase 8, and Fas-associated death domain protein (FADD); and transcription factors such 
as c-Rel, ReIB, NFKB, and B cell-specific activator protein (BSAP); in B cell proliferation 
(208, 210, 224-234). There is some evidence that the murine B cell response to LPS is 
influenced by MHC class II haplotypes (235). 
Induction ofproliferation by epG DNA 
DNA containing unmethylated CpG motifs, i.e. bacterial chromosomes, is also known 
to stimulate B cell activation and proliferation (236-239). Concentrations of DNA 
fragments containing CpG motifs are increased in the circulations of SLE patients and are 
thought to contribute to pathogenesis of the disease (240). Also, administration of CpG 
DNA to SLE-prone mice prompts the onset of nephritis, and CpG DNA from SLE patient 
sera induces proliferation ofPBMC (240, 241). CpG DNA interacts with Toll-like receptor 
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9 (TLR9) to initiate a signaling pathway similar to that activated by TLR4 ligation (92). 
This pathway begins with internalization of CpG DNA to the endosomal compartment 
(238,242). MAPK kinases 3 (MKK3), 4 (MKK4) , and 6 (MKK6) are activated and the 
signaling pathway merges with that initiated by BCR crosslinking at the activation of c-Jun 
N-terminal kinase (JNK) and p38, whose effects lead to the activation of transcription 
factors like NFKB and AP-1 (222, 238). 
Induction ofproli(eration by P MAlion 
Phorbol myristate acetate (PMA) and ionomycin bypass signaling events that occur at 
the cellular membrane, including PTK activity and phosphatidylinositol turnover, to induce 
proliferation (218, 243, 244). These compounds are internalized to the cytosol where PMA 
directly activates PKC and ionomycin transports Ca2+ from outside the cell through the 
cellular membrane (243, 245, 246). Beyond this point, the MAPK pathway is activated, as 
it is through BCR ligation. In a study of B cell gene expression in response to several 
stimuli, including anti-IgM, LPS, and CpG DNA, the majority of genes up- or down-
regulated were so in response to all three mitogens, though to varying degrees (247). This 
data suggests similarity among the pathways activated by these mitogens. 
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Methods 
Manipulation of the murine Fli-l gene 
Derivation of Fli-l+l- MRLIlpr, Fli-l+l- C57BL/6, and Fli_illCTNllCTA C57BL/6 mice was 
previously described elsewhere (188, 197, unpublished). Briefly, a floxed neo cassette was 
used to disrupt ex on IX of the Fli-l gene, by insertion at an EcoRV site (Figure 1). 
Disruption of this regulatory region significantly reduces FH-l protein stability, effectively 
producing a knockout phenotype. The disrupted gene was cloned into the targeting 
pBSTK9 vector. Vectors were incorporated into murine embryonic stem cells (ES), which 
were selected for expansion based on neomycin resistance. Targeted clones were used to 
generate chimeric morulas, which were implanted in DBAlC57BL/6 females (The Jackson 
Laboratory, Bar Harbor, Maine). As Fli-l-I- mice are nonviable, this approach generated 
C57BL/6 Fli-l+l- mice, which were subsequently backcrossed to the MRLIlpr (The Jackson 
Laboratory, Bar Harbor, Maine) background. Using speed congenics to monitor 
inheritance of disease susceptibility loci for seven generations of backcrossing, MRLIlpr 
Fli-1 protein 
disruption of Fli-1 
excision of neo cassette 
truncated FIi-1 ATA II DBD 
Figure 1. Simplified illustration of the Fli-l protein structure, the disrupted Fli-l gene, partial excision of the 
Fli-l gene, and the resulting truncated Fli-l protein. AT A = amino terminal transactivation domain, DBD = 
DNA-binding domain, eTA = carboxy terminal transactivation domain. 
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Fli-l+l- mice were developed. 
Th Fl ' 1 . Fl' l~cTN~cTA' d' d . "1 h d e . 1- gene m 1- . mIce was Isrupte In a SImI ar manner to t at use to 
generate Fli-l+l- mice. However, 10xP-/Cre-mediated excision of the disrupted exon 
resulted in expression of a truncated Fli-1 protein, lacking the C-terminal transactivation 
domain (unpublished data) (Figure 1). 
To generate conditional Fli-1 knock-out mice, a mouse 129SvEv BAC library (248) was 
used to isolate genomic clones. After subcloning of exons 3 and 4 into a pZero-2 vector 
(Invitrogen), an frt-neo-frt-loxP cassette and a second 10xP element were inserted at the 
EcoR! site downstream of ex on 4 and a Scal site 
upstream of exon 3. ES cells from 129/01a mice 
were transfected with the vector by 
electroporation and selected by neomYCIn 
resistance. Transfection with a flippase 
expression plasmid facilitated removal of the neo 
cassette and sensitive cells were inj ected into 
'S7BL/6 blastocysts. Chimeras capable of 
-4ansmitting the floxed allele were backcrossed to 
C57BL/6 mIce for 6 generations. Cre 
recombinase expression was driven by interferon 
production following intraperitoneal injection of 
100 J.lI 2.5 mg/ml poly inosine/poly cytosine 
(PlpC) (Sigma) on days 1, 4, and 7, prior to 
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A 1 2 3 4 5 
B 1 2 3 4 5 
Lane 1 2 3 4 5 
Fli-J +/- +/- +/- +/+ +i+ 
MxCre + + + + -
Flox + + - + -
pIpC injection + + + + -
Figure 2. Efficiency of Cre-mediated excision 
of floxed Fli-l. Expression of 50 kD protein 
detected by Western blot with anti-Fli-l (A) 
and total protein loading detected by ponceau S 
staining (B). n = 1 mouse per lane in a single 
experiment. 
sacrifice on day 10. Efficiency of Cre-mediated removal of the floxed portion of Fli-l was 
determined by western blot of spleen cell nuclear extracts, described below (Figure 2). 
Mice were housed at the Ralph H. Johnson Veterans Affairs Medical Center animal 
facility and bred and sacrificed according to protocols approved by the Institutional Animal 
Care and Use Committee. 
Table 3 outlines the strains, genotypes, and disease status of mice used in the studies 
described here. 
Table 3. Mouse straIns, genotypes, an dd' Isease status. 
strain MRL/lpr C57BL/6 
Fli-J genotype +/+ I +1- +1+ I +/- I ~CTAI~CTA I -I-
SLE YES NO 
DNA extraction 
DNeasy DNA purification kit (Qiagen) was used to extract DNA from tail snIps 
according to the manufacturer's protocol (249). Tails snips were lysed with proteinase K 
overnight. Lysates were passed through a spin column, where DNA became bound to a 
silica-gel membrane and was subsequently eluted. 
Genoryping peR 
As has been previously published (188), DNA extracted from tail snips was subject to 
PCR on a myCycler™ thermal cycler (Bio-Rad) under the following conditions: 1 cycle at 
95°C for 5 min, followed by 39 cycles at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min, 
followed by 1 cycle at 72°C for 7 min, followed by 4°C hold. PCR reagents included lOX 
PCR buffer (Qiagen), 1.8 mM magnesium chloride (MgCh) (Qiagen), 200 f.lM GeneAmp® 
dNTPMix with dTTP (Applied Biosystems), and 2.5 units/reaction Taq DNA polymerase 
(Qiagen). Primers corresponded to exon IX of Fli-l (forward: 
AACGGGGAGTTCAAAATGACG, and reverse: 
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GGAGGATGGGTGAGACGGGACAAAG) and RNA polymerase II (reverse: 
GGAAGTAGCCGTTATTAGTGGAGAGG), part of the vector conferring neomYCIn 
resistance. PCR products were subject to electrophoretic separation in a 2% agarose gel 
(Bio-Rad) in TBE buffer (0.089M Tris (Sigma), 0.089M Boric acid (Fisher), 2mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma), 1% ethidium bromide (Sigma)), for 45 
min at 80V, and visualized by a FotoEclipse™ densitometer (Fotodyne). Presence of a 
single 309 bp fragment indicated a wild-type Fli-l genotype, whereas presence of both a 
309 bp and a 409 bp fragment indicated heterozygous Fli-J genotype. 
Spleen preparations 
Under sterile conditions, lymphocyte suspensions were prepared by crushing fresh 
spleens between frosted glass slides in RPMI 1640 cell culture medium (Mediatech). 
Following a 5 min centrifugation at 1200 rpm, medium was removed, and red blood cells 
were lysed by resuspension in a 9: 1 mixture of 0.16M ammonium chloride (Sigma) and 
0.17M Tris, pH 7.6. Cells were washed twice and resuspended in RPMI 1640 and counted 
by hemacytometer. 
Nuclear protein extraction 
Nuclear protein was extracted from spleen cells according to manufacture's directions 
with NE-PER® nuclear and cytoplasmic extraction reagents (Pierce) supplemented with 
protease inhibitor cocktail (Sigma) per manufacturer's suggestions (250, 251). 
Protein quantification 
Lysates were serially diluted 1:2 with sterile water and subjected to a micro BCA™ 
protein assay (pierce) according to manufacturer's protocol (252). Absorbances at 540 run 
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were measured on a Multiskan® MCC/240 (Titertek) mircoplate reader and concentrations 
were determined by comparison to a bovine serum album (Pierce) standard curve. 
Western blotting 
Volumes of nuclear extract equivalent to 25 J.!g of protein were diluted 1:3 in sample 
buffer (62.5 mM Tris-hydrochloride (HCI) (Sigma) pH 6.8, 2% sodium dodecyl sulfate 
(SDS) (Sigma), 25% glycerol (Sigma), 0.01 % bromophenol blue (Sigma» and 5% ~-2-
mercaptoethanol (Sigma) and run on a 4-20% Tris-HCI Criterion precast gel (Bio-Rad) in a 
Criterion electrophoresis chamber (Bio-Rad) at 200 V for 1 hr, in running buffer (25 mM 
Tris, 192 mM glycine (Fisher), 0.1 % SDS) according to manufacturer's suggestions (253, 
254). The gel was subsequently equilibrated in transfer buffer (25 M Tris, 192 mM 
glycine, 10% methanol (Sigma» for 15 minutes and transferred to a methanol-activated 
Immobilon™-FL PDVF membrane (Millipore) in a Criterion blotter (Bio-Rad) at 400 rnA 
for 1 hr, according to manufacturer's instructions (255). The membrane was blocked 
overnight at 4°C in Odyssey® blocking buffer (LI-COR). Anti-Fli-l(Santa Cruz 
Biotechnology), diluted 1 :200, and 0.1 % Tween 20 (Sigma) were added to blocking buffer 
and incubated overnight at 4°C. The membrane was washed four times in phosphate 
buffered saline (PBS) (137 mM sodium chloride (NaCl) (Fisher), 2.7 mM potassium 
chloride (KCI) (Sigma), 4.3 mM disodium hydrogen phosphate (Na2HP04) (Sigma), 1.47 
mM potassium dihydrogen phosphate (KH2P04) (Fisher) pH 7.4) for 5 min at room 
temperature. The membrane was incubated with Alexa Fluor® 750-labeled goat anti-rabbit 
IgG (Molecular Probes) diluted in Odyssey® blocking buffer at 1: 10,000 with 0.1 % Tween 
20, for 1 hr at room temperature. The membrane was washed four times in PBS for 5 min 
at room temperature and scanned by an Odyssey® infrared imager (LI-COR) according to 
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manufacturer's directions (256). Equal protein loading was assessed by incubating the 
membrane for 30 min at room temperature in ponceau S (Sigma) total protein stain, 
followed by three lOs rinses in deionized distilled water. 
B cell isolation 
NaIve B cells were isolated by negative selection with CD43 Microbeads (Miltenyi 
Biotec) according to manufacturer's directions (257). Briefly, spleen cells were 
resuspended in sterile MACS® buffer (PBS with 2mM EDT A and 0.5% fetal bovine serum 
(FBS) (Hyclone)), allowed to conjugate with anti-CD43-coated iron-imbedded polymer 
beads, and passed through a separation column held by a magnet. Columns were rinsed 
with MACS® buffer according to manufacturer's directions (257). Purity of isolated cells 
was confirmed by staining with peridinin 
chlorophyll-alpha protein (perCP)- or 
allophycocyanin (APC)-labeled anti-B220 or anti-
CD19 (BD Pharmingen) and phycoerythrin (PE)-
labeled anti-CD43 (Miltenyi Biotec or BD 
Pharmingen) and detection by a FACSCalibur™ 
instrument (BD Biosciences). Each sample was 
determined to consist of >90% naIve B cells (Figure 
3). 
Proliferation assays 
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Figure 3. Representative purity of naIve 
B cell popUlation following isolation by 
CD43 microbeads. n = 1, representative 
of 307 individual experiments. 
NaIve B cells were cultured in supplemented RPMI 1640 (1 % 100x nonessential amino 
acids (JRH biosciences), 1 % 100x sodium pyruvate (JRH biosciences), 1 % penicillin 
streptomycin (Mediatech), 1 % N-2hydroxyethylpiprazine-N' -2-ethanesulfonic acid 
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(Mediatech), 10% FBS, and 1x10-5M ~-2-Mercaptoethanol (Sigma)) in duplicate at 2x105 
ceillmi in a 96-well culture plate (Corning) with 0.5, 1, 5, or 1 0 ~glml LPS (Sigma), 1, 5, or 
10 ~glml anti-IgM (Jackson ImmunoResearch), 10 nglml PMA (Sigma) and 0.25, 0.5, or 1 
~g/ml ionomycin (Sigma), or 1, 5, or 10 ~g/ml CpG oligonucleotides (Cell Sciences) 
(258). Cultures were incubated at 37°C in 5% C02 for 48 hours prior to addition of 5 
JlCilml tritiated thymidine and incubation at 37°C in 5% C02 for 14 hours (259). Cells 
were harvested and proliferation determined by a Packard TopCount scintillation counter 
(perkinElmer). Figure 4 illustrates representative dose responses of naIve B cells to anti-
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Figure 4. Dose response of naIve B cells from 20 week old Fli-l+l+ (n = 3) versus Fli-J+I. (n = 3) MRL//pr 




Analysis of data by Mann-Whitney test was perfonned uSIng Prism software 
(GraphPad). A p value of <0.05 was considered significant. 
Results 
To investigate the effects of reduced Fli-l expression on B cell proliferation in the 
context of murine SLE, naIve B cells from Fli-l+l- (n = 2-3) versus Fli-l+l+ (n = 2-3) 
MRLllpr mice were stimulated with LPS, anti-IgM, CpG DNA, or PMA and ionomycin 
(PMAIion), and proliferation was assessed by tritiated thymidine uptake assays. NaIve B 
cells were studied to ensure fair comparison of Fli-l+l- and Fli-l+l+ mice. Presumably, more 
activated B cells are present in wild-type mice, as disease is more severe and/or progresses 
faster. Use of naIve B cells for these studies ensures that proliferative activity observed is a 
result of controlled in vitro stimulation, as opposed to in vivo activation by unknown 
stimuli. Mice were sacrificed for these assays at three ages representing different stages of 
disease. At 6 weeks of age, few indications of disease are present. At 12 weeks of age, 
manifestations of SLE are emerging. At 20 weeks of age, SLE is advanced, to the point of 
renal failure and death (121, 260). 
NaIve B cells from Fli-l+l- MRLllpr mice (n = 1-3) proliferated less in response to LPS, 
anti-IgM, PMAIion, and CpG DNA than those from Fli-l+l+ MRLllpr mice (n = 3) of all 
ages (Figure 5). 
C57BL/6 mice were sacrificed at ages corresponding to those at which MRLllpr mice 
were sacrificed, though age was not expected to affect the activity of B cells from these 
mice. At 6 weeks of age, naIve B cells from Fli-l+l- C57BL/6 mice (n = 3) proliferated less 
in response to LPS and anti-IgM than naIve B cells from Fli-l+l+ C57BL/6 mice (n = 3) 
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(Figure 6A). Heterozygous and wild-type responses to PMAlion and CpG DNA were 
relatively similar. Compared to wild-type (n = 2-3), heterozygous cells (n = 2-3) also 
proliferated less in response to LPS, CpG DNA, and anti-IgM at 12 weeks of age (Figure 
6B). Twenty-week-old heterozygous B cells (n = 2-3) proliferated less than wild-type cells 
(n = 2-3) in response to PMAlion and anti-IgM, but not in response to LPS and CpG DNA 
(Figure 6C). 
NaIve B cells from 6-week-old Fli_l/).cTAI/).cTA C57BL/6 mice (n = 3) proliferated less, 
compared to Fli-l-wild-type C57BL/6 B cells (n = 3), in response to anti-IgM, PMAIion, 
and CpG DNA, but not LPS (Figure 7A). At 12 and 20 weeks of age, naIve B cells from 
Fli_l/).cTAI/).cTA C57BL/6 mice (n = 2-3) proliferated less than those from Fli-l+l+ C57BL/6 
mice (n = 2-3) in response to all mitogens (Figure 7B and 7C). 
NaIve B cells from 8-week-old C57BL/6 conditional Fli-J knockout mice (n = 3) 
proliferated less in response to anti-IgM and PMAIion compared to wild-type C57BL/6 B 
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Figure 5. Proliferative response ofMRL/lpr Fli-l+l+ (n = 3) versus Fli-l+l- (n = 1-3) B cells to mitogens at 
(A) 6, (B) 12, and (C) 20 weeks of age. Data from 1-3 experiments in duplicate is shown as mean CPM 
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Figure 6. Proliferative response of C57BL/6 Fli-l+l+ (n = 2-3) versus Fli-l+l- (n = 2-3) B cells to 
mitogens at (A) 6, (B) 12, and (C) 20 weeks of age. Data from 1-3 experiments in duplicate is shown as 
mean CPM ± SEM. * = () < 0.05. 
35 
B 
·7B 6 Fli- I 
·7BLI f7i-1 
wks 
5 7 B L/ l f Ii -I 
-7BLI Fli-I CT.\ 'T.\ 
12 wk 
- C:7B J-/i-I 
D T .\ ( 1". \ 57BLI FII-1 
_ ),,"k 
Figure 7. Proliferative response of C57BL/6 Fli-l+l+ (n = 2-3) versus Fli_l/lCTNtlCTA (n = 2-3) B cells to 
mitogens at (A) 6, (B) 12, and (C) 20 weeks of age. Data from 1-2 experiments in duplicate is shown as 
mean CPM ± SEM. * = P ~ 0.05. 
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Figure 8. Proliferative response of C57BL/6 Fli-J+I+ (0 = 3) versus Fli-rl- (0 = 3) B cells to mitogeos at 
8 weeks of age. Data from one experiment in duplicate is shown as mean CPM ± SEM. * = P ~ 0.05 . 
Conclusions 
Regardless of strain, age, or genotype, all responses to anti-IgM were inferior to that of 
CpG DNA and LPS (Figures 5-8). As previously noted, proliferative response to anti-IgM 
may vary according to the specificity and avidity of the antibody (215, 216). Also, 
induction of proliferation by anti-IgM is known to be enhanced by accessory cells and T 
cell-derived factors, including B cell growth factor and interleukin 1, whose presence is 
likely limited in these purified B cell cultures (261-263). The varied success of stimulation 
with PMAlion is also noted and the decreased stability of these compounds in long-term 
storage may be responsible (Figures 5-8). 
As shown in the figures, statistical significance was not consistently attained, possibly 
due to the small sample size. The power of these statistical analyses could certainly be 
increased by larger numbers of mice. However, our effort to compare siblings as often as 
possible, coupled with limited mouse availability and an effort to avoid interexperimental 
variation did not allow for larger sample sizes. 
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It is noted that statistical significance was observed more frequently in the younger 
MRLllpr groups than the oldest age group (Figure 5). Significant differences in MRLllpr 
B cell proliferation are perhaps not detected at this age because disease in the heterozygotes 
has progressed to a point more equivalent to that of wild-type mice. Alternatively, 
significant differences may not be observed because as wild-type MRLllpr mice age, the 
ability of their B cells to respond to proliferative stimuli decreases, potentially equalizing 
the proliferative responses of Fli-l+l- and wild-type cells (264-266). The observation of 
significant differences in proliferation in the oldest groups of C57BL/6 mice lends support 
to these hypotheses, as all three ages are relatively young in the life of a C57BL/6 mouse, 
and differences in B cell function at these ages has not been described (Figure 6). It is also 
noted that more significant differences in proliferation were observed when comparing Fli-
l!J.cTN!J.cTA to wild-type C57BL/6 mice than when comparing Fli-l+l - to wild-type C57BL/6 
mice (Figures 6 and 7). These findings suggest that B cell proliferation is affected more 
severely by the decreased transcriptional activity of the mutant Fli-l than by the reduced 
expression of normal Fli-l and possibly that the Fli-l carboxy-terminus plays a more 
pivotal role in B cell proliferation than does the amino-terminus. Also, as previously 
discussed, Fli-l binding sites may be occupied by other ETS factors in the Fli-l+l- mice, 
while this is less likely to occur in Fli_lIlCTA/!J.CTA mice. 
In consideration of Aim la, significantly reduced proliferative responses to mitogens 
were observed overall in Fli-l+l- MRLllpr B cells compared to wild-type MRLllpr B cells 
(Figure 5). These data suggest that Fli-l deficiency results in decreased B cell proliferation 
in lupus-prone MRLllpr mice. Proliferation initiated by the mitogens used here, if not by 
all means of initiation, is affected, suggesting that Fli-l regulates B cell genes which 
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directly or indirectly influence B cell proliferative responses. Fli-l may regulate a number 
of genes, thus impacting multiple proliferative pathways, or it may regulate one gene 
critical to all pathways. 
In consideration of Aim 1 b, proliferative responses from Fli-l+l- and Fli_lI1CTAJI1CTA 
C57BL/6 B cells were significantly reduced compared to responses from wild-type 
C57BL/6 B cells (Figure 6). These data not only reiterate the conclusions of Aim 1 a, but 
also suggest that the influence of Fli-l on B cell proliferation is part of normal immunity, 
not merely a consequence of disease. However, the impact on B cell proliferation was 
slightly more profound in MRLIZpr mice, suggesting that the SLE phenotype somewhat 
accentuates the effects of Fli-l deficiency. One fundamental difference between MRLllpr 
and C57BL/6 B cells is the lack of Fas on MRLllpr cells. This is a possible contributing 
factor. 
In consideration of Aim lc, some proliferative responses of Fli-l-deficient MRLllpr B 
cells were significantly reduced compared to wild-type B cell responses at all ages 
examined, beginning at 6 weeks (Figure 5). If in fact the role of Fli -1 in B cell proliferation 
has an impact on SLE development and progression, these data suggest that abnormal 
expression of Fli-l is likely to contribute to causal events, as proliferation appears to be 
affected prior to onset of disease. 
Taking together these conclusions, we believe that Fli-l activity regulates genes that 
influence B cell proliferation regardless of presence or absence of SLE, and that abnonnal 




EFFECT OF FLI-I DEFICIENCY ON MITOGEN RECEPTOR EXPRESSION 
Aims and Rationale 
Aim 2a: To assess the effect ofFli-l deficiency on BCR expression. 
Fli -I-deficient B cells proliferated less than wild-type B cells in response to anti -IgM 
and the expression of Iga, an integral BCR component, is known to be regulated in part by 
Fli-l (169). It was therefore hypothesized that a mechanism behind the observed defect in 
anti-lgM-stimulated proliferation is decreased or incomplete BCR expression. Reduced 
expression ofBCR components on Fli-l-deficient B cells was expected. 
Aim 2b: To assess the e(fect ofFli-l deficiency on TLR4 expression. 
The proliferative response of Fli-l-deficient B cells was reduced compared to that of 
wild-type B cells in response to the TLR4 ligand LPS. Similar to our hypothesis regarding 
BCR expression, it was suspected that a potential mechanism driving this phenomenon is 
reduced expression of TLR4 on Fli-I-deficient B cells. 
Aim2c: To assess the effect ofFli-l deficiency on TLR9 expression. 
SLE patients with active disease demonstrate higher proportions of B cells expressing 
TLR9 compared to patients in a remissive state (267). TLR9 expression also correlates 
with anti-dsDNA, indicating a potential role for this receptor in disease activity. 
Considering our observation that Fli-l-deficient B cells proliferate less than wild-type B 
cells in response to the TLR9 ligand CpG DNA, it was hypothesized that Fli-l-deficient B 
cells, as with BCR and TLR4, would demonstrate reduced expression ofTLR9. 
Background 
BCR expression. Anti-IgM stimulates B cells to proliferate through crosslinking BeRs. 
A complete BCR is comprised of a surface IgM molecule flanked by two accessory protein 
heterodimers, Ig~ and 19B. Ig~ is not only needed for expression of the BCR, but also for 
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function of the receptor (268). The cytoplasmic tail of Iga is necessary for the intracellular 
signaling following BCR ligation that results in activation (269). Direct effects of BCR 
expression on SLE development have yet to be reported, but the role of BCR in B cell 
activity, defects of which are associated with the disease, is firmly established. 
TLR4 expression. Toll-like receptors are an important component of innate and adaptive 
immunity that facilitate nonspecific recognition of pathogens (270). LPS activates B cells 
though ligation of TLR4 (271). It has been postulated that stimulation of B cells through 
this interaction may play a significant role in renal disease development (272). In clear 
confirmation that TLR4 expression influences SLE development, mice possessing multiple 
copies of the gene encoding TLR4 demonstrate lupus-like autoimmunity indicated by 
elevated IL-12 p40 production in response to LPS, production of anti-dsDNA, and 
deposition of immune complexes in the kidney (273). 
TLR9 expression. CpG DNA interacts with TLR9 to initiate a signaling pathway similar 
to that activated by TLR4 ligation (92). Elevated expression of intra-B cell TLR9 and a 
correlation between percentage of TLR9 expressing B cells and the presence of anti-
dsDNA was identified in SLE patients (93, 267). Also, TLR9 mRNA expression in B cells 
increases in the presence of interferon y (IFNy), a cytokine known to be elevated in SLE 
patient serum (274, 275). In autoreactive B cells, TLR9 signaling is necessary for class 
switching to pathogenic immunoglobulin subclasses IgG2a and IgG2b (275, 276). 
Together, these studies suggest a potential role for TLR9 expression in SLE development. 
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Methods 
FACS analysis of surface receptor expression 
2xl07 naIve B cells/ml were resuspended in sterile FACS buffer (PBS with 1% sodium 
azide (Sigma) and 0.1 % FBS). 1 J.lI anti-CD 16/CD32 (BD Phanningen) per 106 cells was 
added and incubated on ice for 20 minutes. 0.5 Jlg/ml PE-Iabeled anti-C043 (Miltenyi 
Biotec, BD Pharmingen), APC-Iabeled anti-CD19 (BD Phanningen), PerCP-Iabeled anti-
B220 (BD Phanningen), APC-Iabeled anti-IgM (eBioscience, BD Phanningen), unlabeled 
or APC-Iabeled anti-CD79a (Anaspec, BD Phann ing en) , biotin- or fluorescein 
isothiocyanate (FITC)-labeled anti-TLR4 (eBioscience, Imgenex), andlor unlabeled or 
FITC-Iabeled anti-TLR9 (eBioscience, Imgenex) were added to 0.5-1xl06 cells and 
incubated on ice for 20 minutes, protected from light. Following two washes in F ACS 
buffer, 0.5 Jlg/ml FITC-labeled anti-rabbit IgG (Abeam), andlor APC-Iabeled streptavidin 
(BO Biosciences) were added where appropriate and incubated on ice for 20 minutes, 
protected from light. Following two washes with FACS buffer, fluorescence was detected 
by a F ACSCalibur™ flow cytometer. 
FACS analysis of intracellular receptor expression 
2xl07 naIve B cells/ml were resuspended in sterile FACS buffer. 0.5 Jlg/ml PE-Iabeled 
anti-CD43 and APC-Iabeled anti-CDl9 or PerCP-Iabeled anti-B220 (BO Pharmingen) was 
added to 0.5-1xl06 cells and incubated on ice for 20 minutes, protected from light. 
Following two washes with FACS buffer, cells were incubated in fixation buffer 
(eBioscience) according to manufacturer's protocol, for 20 minutes at room temperature 
(277). Cells were then washed twice in penneabilization buffer (eBioscience) and stained 
with unlabeled or FITC-Iabeled anti-TLR9 according to manufacturer's protocol (278). 
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Staining with FITC-Iabeled anti-rabbit IgG where appropriate followed two washes in 
permeabilization buffer. Cells were resuspended in F ACS buffer and fluorescence was 
detected by F ACSCalibur™ flow cytometer. 
Results 
To examine the effect of Fli-1 deficiency on BCR expression, IgM and Iga expression 
on naIve B cells from 6-, 12-, and 20-week-old Fli-l+l- (n = 1-5) versus Fli-l+l+ (n = 1-5) 







































































Figure 9. Expression of IgM and Iga on the surface of naIve B cells from Fli-l+l+ (area filled) 
versus Fli-l+l- (area open) MRL/lpr mice. Images represent one of 1-5 animals in each group in 1-
4 independent experiments. Dotted line represents secondary antibody control. 
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unchanged, on Fli-l+l- cells from 20-week-old mice (n = 1-3), while Iga was slightly 
reduced, and IgM was unchanged, compared to wild-type (n = 1-5), on Fli-l+l- B cells from 
6-week-old mice (n = 1-5) (Figure 9). Neither IgM nor Iga expression appeared to be 
affected by Fli-1 deficiency at 12 weeks of age (Figure 9). Because IgM and Iga are 
expressed in conjunction as the BeR, these results were unexpected. However, Iga is also 
known to associate with IgD on naIve B cells, and dissimilar IgD expression may account 
for the observed differences in Iga expression while IgM expression remains unaffected 
(279). IgD expression did not appear to be altered on Fli-1 deficient cells from MRL/lpr 
mice of any age (Figure 9). 
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Figure 10. Expression of IgM, Iga, and IgD on naIve B cells from C57BL/6 Fli-J+I+ (area filled) 
versus Fli-l+l- (area open) mice. Images represent one of 1-3 animals in each group in 2-5 
indeoendent exoeriments. 
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At 20 weeks of age, IgM expression was slightly reduced on C57BL/6 Fli-J +I- (n = 3) B 
cells compared to wild-type (n =- 3), but appeared to be similar at 6 and 12 weeks of age 
(Figure 10). IgD expression was slightly reduced on B cells from 12-week-old C57BL/6 
Fli-J+I- mice (n = 2-3) compared to those from wild-type C57BL/6 mice (n = 2-3), but 
appeared to be similar at 6 and 20 weeks of age (Figure 10). Iga expression was slightly 
reduced on Fli-J+I- B cells from 6- (n = 2-3) and 20- (n = 3) week-old C57BL/6 mice, 
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Figure t 1. Expression of IgM, Iga, and IgD on naIve B cells from C57BL/6 Fli-l+l+ (area filled) 
versus Fli_l I::J.CTNI::J.CTA (area open) mice. Images represent one of 1-5 animals in each group in 1-5 
independent experiments. 
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Upon comparison of B cells from C57BL/6 Fli-l +l+ (n = 3-5) and Fli_l !1CTN!1CTA (n = 3-
5) mice, differential expression of IgM, Iga, and IgO was observed at 6 weeks of age 
(Figure 11). Similar to experiments represented in Figures 9 and 10, differences in 
expression were minimal. IgM, Iga, and IgO expression on Fli-l +l+ (n = 2) and Fli-
1 CTN!1CTA (n = 2) cells was similar at 12 weeks of age. At 20, Iga and IgO expression was 
similar, while IgM expression actually appeared to be increased on Fli_l !1CTN!1CTA (n = 1-3) 
























































Figure 12. Expression of TLR4 and TLR9 (s - surface, ic - intracellular) on na"ive B cells from 
MRLllpr Fli-/+I+ (area filled) versus Fli-/ +I- (area open) mice. Images represent one of 1-3 
animals in each group in 1-3 independent experiments. Dotted line represents secondary antibody 
control. 
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To examine the effect of Fli-1 deficiency on expression of TLR4 and TLR9, expression 
of these receptors on naIve B cells from Fli-l+l+ (n = 1-3) versus Fli-l+l- (n = 1-3) MRLllpr 
mice at 6, 12, and 20 weeks of age was determined. Slightly reduced expression of TLR4 
was noted on Fli-l+l- B cells, compared to wild-type B cells, at the ages of 6 and 20 weeks, 
while it appeared to be slightly increased at 12 weeks (Figure 12). Much of the current 
literature regarding TLR9 asserts that it is expressed primarily intracellularly and CpG 
DNA must be taken into the endosome to initiate signaling associated with TLR9 (280-











































































Figure 13. Expression of TLR4 and TLR9 (s - surface, ic - intracellular) on naiVe B cells from 
C57BL/6 Fli-J+I+ (area filled) versus FIi-J+I- (area open) mice. Images represent one of2-3 animals 
in each group in 2-5 independent experiments. 
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dendritic cells, and B cell lines, TLR9 has also been detected on the surface of primary B 
cells in a number of studies (283, 284). In light of this controversy, both surface and 
intracellular expression of TLR9 were assessed. Compared to Fli-l-wild-type B cells (n = 
1-3), surface expression of TLR9 on B cells from Fli-l+l- MRLllpr mice (n = 1-3) was 
slightly reduced at all three ages and intracellular expression of TLR9 was reduced in Fli-l-
deficient cells from mice 12 and 20 weeks of age, and unchanged in Fli-l deficient cells 
from mice 6 weeks of age (Figure 12). 
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Figure 14. Expression of TLR4 and TLR9 (s - surface ic - intracellular) on naIve B cells from 
C57BL/6 Fli-J +/+ (area filled) versus FIi_J IlCTAlIlCTA (area open) mice. Images represent one of 2-5 
animals in each group in 1-4 independent experiments. 
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naIve B cells demonstrated a slight reduction on Fli-l-deficient B cells at 6 and 20 weeks of 
age, comparable to the observations made evaluating TLR4 expression on Fli-l+l+ versus 
Fli-l+l- MRLI/pr B cells (Figure 13). TLR4 expression appeared unaffected on Fli-l-
deficient cells at 12 weeks of age (n = 2-3). Surface expression ofTLR9 was also slightly 
reduced on Fli-l-deficient B cells at the age of 6 weeks, but similar to wild-type at 12 and 
20 weeks, while intracellular expression of TLR9 was slightly reduced at all ages (Figure 
13). 
Surprisingly, only TLR9 surface expression appeared to be slightly reduced on Fli-
l'lCTA/IlCTA (n = 1-5) C57BL/6, compared to wild-type (n = 1-5) B cells, at 6 and 20 weeks 
of age (Figure 14). Unlike Fli-l+l - MRLllpr and C57BL/6 B cells, Fli_lIlCTAlIlCTA cells 
demonstrated no discernible reduction in TLR4 or intracellular TLR9 expression at any age 
(Figure 14). 
Conclusions 
In consideration of Aim 2a, slightly reduced expression of BCR components IgM and 
Iga on B cells of 6-week-old Fli_lb.CTAlb.CTA C57BL/6 and 20-week-old Fli-l+l- C57BL/6 
mice was observed (Figures 10 and 11). Iga alone was slightly reduced on B cells of 6-
week-old Fli-l+l- MRLIZpr and C57BL/6 mice, while IgM alone was slightly reduced on B 
cells of20-week-old Fli-l+l- MRLI/pr mice (Figures 9 and 10). 
In addition, IgD was slightly reduced on Fli-l-deficent C57BL/6 B cells from 12-week-
old mice, on which decreased expression Iga was not demonstrated (Figure 10). Reduced 
IgD expression was concurrent with reduced Iga expression on B cells from 6-week-old 
Fli_lIlCTAlb.CTA mice, but IgM expression was also reduced (Figure 11). Were the reduced 
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expression of Iga due to faulty association with IgO but not IgM, or vice versa, nonnal 
expression of either IgM or IgD and reduced expression of the other would be expected. 
As this was not observed, it is unlikely that Fli-1 deficiency affects Iga expression in this 
manner. 
Given that Iga is known to be regulated by Fli-1, a more impressive reduction of Iga 
expression was expected (169). Like any model system, those used in these experiments 
are not without limitations. Fli-l-heterozygous cells still express nonnal Fli-1 protein, 
though the quantity is reduced by half. Fli_lt1CTAlt1CTA cells express a nonnal quantity of 
Fli-l protein, but the functionality is reduced by half. Perhaps the quantity or functionality 
possessed by these models remains above the threshold necessary for nonnal or near 
normal expression of Iga, as well as expression of the other mitogen receptors measured 
here. Fli-1 is certainly not the only regulator of Iga expression, so other transcription 
factors may compensate for the Fli-l deficit, as expression of BeR is essential for the 
development and survival of B cells. Alternatively, our method of analysis may be 
insufficient to detect subtle but significant differences in expression, though we believe this 
is unlikely. 
Overall, it is concluded that these data do not support the hypothesis that reduced BCR 
expression is a major mechanism behind the reduced proliferation of B cells from Fli-l-
deficient mice in response to anti-IgM. If these results accurately reflect in vivo BCR 
expression, the idea that this reduced expression may contribute to the observed 
proliferation assay results cannot be discounted, though to what extent can not be 
speculated. 
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In consideration of Aim 2b, slightly reduced expression of TLR4 on Fli-l+l- MRL/Zpr 
and C57BL/6 B cells from mice of 6 and 20 weeks of age was observed (Figures 12 and 
13). Of the mitogen receptors examined, TLR4 expression, along with IgM, was least 
often decreased on Fli-l-deficient cells (Figures 9-14). However, proliferative responses of 
Fli-l-deficient B cells to LPS, a ligand of TLR4, were most often reduced (Figures 5-7). 
We therefore believe it is unlikely that reduced TLR4 expression is a major mechanism 
driving the reduced proliferative response of Fli-I-deficient cells to LPS. The data do not, 
however, disprove that a slight reduction of TLR4 expression may have some impact on 
response to LPS in Fli-l-deficient cells. As discussed concerning BCR expression, Fli-l 
expression and activity in these models may remain above the threshold necessary for 
TLR4 expression, and other transcription factors that regulate TLR4 expression may offset 
Fli-l deficiency. 
In consideration of Aim 2c, slightly reduced expression of TLR9 was observed on the 
surface of Fli-l+l- B cells from all ages of MRLllpr mice, Fli-l+l- B cells from 6-week-old 
C57BL/6 mice, and Fli_ltJ.cTNtJ.cTA B cells from 6- and 20-week-old C57BL/6 mice 
(Figures 12-14). Slightly reduced expression of intracellular TLR9 was also observed in 
Fli-l+l- B cells from 12- and 20-week-old MRLllpr and all ages of C57BL/6 mice (Figures 
12 and 13). However, Fli-l-deficient mice in which proliferative response of B cells to 
CpG DNA, a ligand of TLR9, demonstrated a decrease did not always correlate with those 
in which reduced TLR9 expression, either surface or intracellular, was observed. Fli-l+l- B 
cells from 6-week-old MRLllpr and 6- and 20-week-old C57BV6 mice demonstrated 
reduced TLR9 expression, but did not demonstrate reduced proliferative response to CpG 
DNA (Figures 5, 6, 12, and 13). It is therefore concluded that reduced TLR9 expression is 
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unlikely to impart a major influence on the response of Fli-I-deficient B cells in response 
to CpG DNA 
The overall conclusion drawn from Aims 2a, 2b, and 2c is that reduced expression of 
mitogen receptors is unlikely to be the mechanism behind the large differences in B cell 
proliferation presented in Figures 5-7. The differences in expression of mitogen receptors 
presented in Figures 9-14 are small and their significance is questionable. But again, this 
may be a caveat of the models used and Fli-I expression and activity may be above the 
threshold necessary for somewhat normal expression of these mitogen receptors. However, 
like the results of the proliferation assays, differences in mitogen receptor expression, when 
present, were more appreciable in B cells from MRLI/pr mice than in cells from C57BL/6 
mice. As discussed earlier, potentially the lack of Fas, or others aspects of the SLE 
phenotype may accentuate the effects of FH -1 deficiency. 
53 
Chapter 4 
EFFECT OF FLI-I DEFICIENCY ON EXPRESSION OF SIGNALING AND 
EFFECTOR PROTEINS ASSOCIATED WITH B CELL PROLIFERA IION 
Aims and Rationale 
Aim 3: To assess the elJect ofFli-1 deficiency on expression ofBCR and TLR signaling cascade 
and effector proteins 
B cell proliferation in response to mitogens is clearly affected by Fli-I deficiency, but 
minimal decreases in mitogen receptor expression on FH-I-deficient cells suggest that more 
profound effects of Fli-I deficiency may be found downstream. Also, significantly reduced 
proliferative responses to all mitogens tested were noted, including PMAIion which bypass 
interaction with cell surface receptors. Therefore, Fli-I deficiency likely affects proliferation via 
mechanisms other than inadequate receptor expression. Furthermore, both BCR and TLR 
pathways are affected. It was therefore predicted that expression of signaling and effector 
proteins common to both these pathways is limited as a result of Fli -1 deficiency. 
Methods 
Collection o(serum 
Whole blood was collected by mandibular vein puncture and, following cervical dislocation 
under anesthesia, heart puncture and allowed to clot at room temperature for 1 hr. Serum was 
separated by centrifugation at 3000 rpm for 15 min and stored at -800 C. 
Preparation of cells for RT-PCR 
B cells were isolated from spleen with CD90 Microbeads (Miltenyi Biotec) and cultured with 
or without 10 J.!g/ml LPS for 62 hrs, as described in Spleen preparations, B cell isolation, and 
Proliferation assays in Chapter 2 methods (285). 
RNA isolation 
RNA was extracted from B cells with Trizol® reagent (Invitrogen) according to 
manufacturer's protocol (286). Briefly, cells were disrupted in Trizol®, RNA was 
55 
dissolved in chloroform (Sigma), the aqueous phase was collected, and RNA was 
precipitated in isopropyl alcohol (Fisher Scientific), washed in 75% ethanol (AAPER), and 
dissolved again in diethylpyrocarbonate (DEPC)-treated water (Fisher Scientific). 
Determining RNA yield 
RNA was diluted in TE:8 buffer (lOmM Tris-hydrochloride, ImM EDTA, pH 8.0) and 
scanned by a SmartSpec ™ Plus (Bio-Rad) spectrophotometer to determine RNA 
concentration and purity by absorbance at 260 nm and the ratio of absorbance at 260 run to 
absorbance at 280 nm according to manufacturer's instructions (287). 
mRNA amplification 
mRNA was amplified according to Invitrogen's SuperScript Indirect RNA 
Amplification kit protocol, doubling length of incubations throughout (288). Briefly, 
mRNA was converted to cDNA using T7-0Iigo(dT) primers to specifically anneal mRNA. 
eDNA was purified by a spin column technique, then transcribed to aRNA on a myCycler™ 
thermal cycler (Bio-Rad). aRNA was purified by spin column and yield was determined as 
described above. 
Real-time RT-PCR 
RNA or aRNA was converted to cDNA according to manufacturer's instructions for the 
RT2 PCR Array First Strand Kit (SuperArray) (289). cDNA was subjected to a Mouse RT2 
RNA QC PCR Array (SuperArray) on a MyiQ real-time PCR detection system (Bio-Rad) 
according to manufacturer's protocol, to determine reverse transcription efficiency., 
amplification efficiency, genomic DNA content, and DNA contamination (290). cDNA 
was then applied to a Mouse Toll-Like Receptor Signaling Pathway RT2 Profiler™ PCR 
Array (SuperArray) according to manufacturer's protocol (289). cDNA was also subject to 
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single RT2 qPCR primer assays in triplicate, using primers for murine csfJ, elfl, il12a, Ita, 
mphosphl, nfatl c, njkbia , njkbl, or tlr9 (SuperArray) according to manufacturer's 
protocol (291). Primers used to detect expression of individual genes included on the 
Mouse Toll-Like Receptor Signaling Pathway RT2 Projiler™ PCR Array were identical to 
those of the array. 
Statistical analysis 
peR array data was scaled and quantile normalized prior to analysis by T test. A p 
value of 0.05 and a fold-change greater than 2 was considered significant. 
Identification of overrepresented transcription factor binding motifs 
MDFrame software was used to identify overrepresented transcription factor binding 
motifs located in conserved promoter regions of differentially expressed genes (292, 293). 
IL12 ELISA 
Serum concentrations of IL12 were evaluated by mouse IL12 p70 ELISA Ready-SET-
Go! kit (eBioscience) according to manufacturer's instructions (). Briefly, 96-well 
microtiter plates (Nunc) were coated with anti-mouse IL 12 p70 diluted 1 :250 in coating 
buffer at 4°C overnight. Following 5 washes in wash buffer, plates were blocked with 
assay diluent for 1 hr at room temperature. Following 5 washes in wash buffer, 2-fold 
serial dilutions of serum in assay diluent were added and incubated at 4°C overnight. 
Following 5 washes in wash buffer, biotin-conjugated anti-mouse IL12 p70 diluted 1 :250 
in assay diluent was added and incubated for 1 hr at room temperature. Following 5 
washes in wash buffer, avidin-horseradish peroxidase (HRP) diluted 1 :250 in assay diluent 
was added for 30 min at room temperature. Following 7 washes in wash buffer, substrate 
solution was added and incubated for 15 min at room temperature. Following addition of 
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stop solution, absorbances at 450 run were measured on a Multiskan® MCC/240 mircoplate 
reader and concentrations were detennined by comparison to a recombinant mouse IL12 
p70 standard curve. 
Results 
The expression of 84 genes related to TLR signaling was detennined in stimulated or 
unstimulated splenic B cells isolated from 6-week-old Fli-l+l+ (n=2) and Fli-l+l. (n=2) 
MRL/lpr mice. Several of these genes are also known to participate in BeR signaling. 
Genes identified as more than 2-fold differentially expressed and statistically significant by 
these arrays and transcription factor binding sites which appear in a majority of the 
promoters of these genes are summarized in Table 4. 
Individual 
Table 4. Expression ofTLR and BeR signaling-related gene in Fli-l+l+ (n = 
+1 2) versus Fli-l - (n = 2) MRLllpr B cells. One experiment per mouse. confinnation of 
LPS Increased expression in MRLllpr Transcription factor binding 
stimulation Fli-l+l - B cells sites present 
cd86 il12a tlr5 c-rel p65 selected genes from 
csj3 il2 tlr9 elf-l Stat! 
- elkl il6 traf6 N Stat5a Table 4 (csj3, il12a, 
ifng Ita ube2n NF-AT 
map3k7 
il12a nfkbl nfrbk c-rel p65 
Ita, tlr9, nfkbl, nfkbia, 
+ Ita nfkbia nr2c2 N Stat5a 
~F-AT elfl, and nfatcl) was 
performed using total RNA from stimulated or unstimulated B cells of 6-week-old Fli-l+l+ 
(n = 5) versus Fli-l+l- (n = 5) MRL/lpr mice. In addition to these genes, differential 
expression ofM phase phosphoprotein 1 (MPPl) transcripts was examined. This gene was 
selected because mphosphl was identified as 182-fold downregulated in murine endothelial 
cells subject to Fli-l knockdown by RNAi (unpublished data). Fold change differences in 
expression from confinnation assays are summarized in Table 5. Expression of il12a, lta~ 
and mphosphl in unstimulated cells and mphosphl and tlr9 in stimulated cells 
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demonstrated greater than two-fold increase in 
Table 5. Expression of selected genes in Fli-l+l+ 
(n = 5) versus Fli-l+/· (n = 5) MRL/lpr B cells. 
confinnation assays. Expression of nfatJ c 0 tr' r t . t ne Ip.lca e expenmen per gene. 
gene 
Fold change in MRL/lpr Fli-l+'- B cells 
Unstimulated LPS Stimulated demonstrated greater than two-fold decrease in 
csj3 1.5 -0.97 
elfl 1.96 1.13 
il12a 2.2 1.2 
stimulated B cells. 
Ita 2.58 1.56 
mphosphl 2.6 2.1 IL 12 was undetectable in serum by ELISA. 
nfatcl -1.01 -2.03 
ELISA kits for murine TNFP are not njkbl 1.78 -0.9 
nfkbia -0.5 1.0 
commercially available. Availability of tlr9 1.58 2.62 
standards and antibodies is limited, and an optimized protocol for detection of TNFP In 
murine serum remains to be developed. Likewise, antibodies for murine mphosphl are not 
currently available, and an optimized protocol for detection remains to be developed. 
Conclusions 
Unexpectedly, TLR and BCR signaling and effector protein genes which were 
differentially expressed in Fli-l+l+ and Fli-J+I- MRLllpr B cells were overexpressed in the 
heterozygous cells (Table 4). Fli -1 is able to act as a repressor of transcription, and perhaps 
this role has been previously underestimated. Alternatively, Fli-l may activate 
transcription of one or more repressors important for the regulation of TLR and BeR 
signaling pathway and effector genes. 
ILI2 is comprised of two subunits, p35, which is specific to ILI2, and p40, which is 
also a subunit of Interleukin 23 (294). Levels of ILl2 p35 mRNA were found to be 
significantly lower in PMBC from SLE patients than in PMBC from healthy subjects (295). 
Also, treatment ofSLE PMBC with ILI2 reduced anti-dsDNA production up to 75% (296, 
297). This effect, as well as reduced lymphadenopathy, splenomegaly, proteinuria, and 
glomerulonephritis, was also observed in vivo upon treatment of MRL/pr mice with 
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monthly injections of an IL12-encoding plasmid (298). These effects of IL12 on SLE 
parameters may contribute to the observed phenotype of Fli-l+l- MRLllpr mice. 
Upregulation of IL12 in Fli-l+l- MRLllpr mice may also contribute to their reduced 
capacity for B cell proliferation, as IL 12 treatment reduces proliferation and tumorgenicity 
of malignant B cells in which IL 12 receptor expression is induced (299). 
TNF~, encoded by the Ita gene, has been shown to enhance B cell proliferation and 
immunoglobulin secretion in vitro (300, 301). However, increased TNF~ has been observed 
in PBMe cultures from hypogammaglobulinemic children and later normalization of 
immunoglobulin production coincided with decreased TNF~ production (302). As 
decreased immunoglobulin production has previously been determined in Fli-l+l- MRLllpr 
sera, upregulation of Ita may contribute to this occurrence. In a Korean population, low 
production of TNFB was associated with SLE and lupus nephritis (303). The role of TNF~ 
in B cell proliferation remains incompletely defined in the literature. One study suggests 
that TNFp alone has little or no effect on B cell proliferation, while another found TNFP to 
be essential for the growth and differentiation of chronic lymphocytic leukemia B cells (304, 
305). The connection between elevated Ita transcripts and the phenotype of the MRL/lpr 
Fli-l heterozygote requires further investigation. 
The role of MPP 1 in microtubule-binding and -bundling is critical to late stages of cell 
division (306). This mitotic molecule motor is upregulated in human bladder cancer and 
knockdown by RNAi results multinucleated cells (307). Given this pivotal role in mitosis, 
and the impressive downregulation of MPPI in endothelial cells subject to Fli-1 
knockdown by RNAi, the potential of MPP1 downregulation in Fli-l+l - B cells to be a 
mechanism driving their impaired proliferation was considered. However, mild 
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upregulation of MPP1 in Fli-l+l- MRLI/pr B cells was observed (Table 5). Factors which 
regulate MPP 1 are unknown. The potential role of Fli-l in this regulation may be cell-
specific. 
As previously discussed, TLR9 recognIzes hypomethylated DNA fragments and 
initiates innate immune responses (91). While B cell expression of TLR9 is increased in 
SLE patients and correlates with presence of anti-dsDNA and it is firmly established that 
ligation of TLR9 with CpO oligonucleotide is a potent means of inciting B cell 
proliferation, absence of TLR9 in lupus-prone mice exacerbates disease, leaving the role of 
TLR9 in SLE development ambiguous (93, 97, 239, 267). The mechanism of protection 
from SLE development offered by TLR9 expression is currently unknown and warrants 
further investigation. 
Nuclear factor of activated T cells (NF A T) is a transcription factor that plays an 
important role in lymphocyte proliferation (308). As its name suggests, NF AT is primarily 
regarded as a T cell protein, though its expression is induced and the protein is active in B 
cells stimulated with anti-IgM and PMA/ion (309, 310). NFAT regulates expression of 
many genes in lymphocytes, including c-myc and BAFF, which are proliferation and 
survival-promoting proteins (311, 312). Expression of c-myc and BAFF in these cells, as 
well as the potential for Fli-1 to regulate NF AT expression, remains to be examined. 
In consideration of aim 3, it cannot be concluded that Fli-l-deficiency induces 
differential regulation of the investigated TLR- and BCR-signaling or effector proteins. 
However, upregulation of the IL12 p35 subunit gene may be of particular interest with 
regard to concurrence of Fli-l deficiency and decreased B cell proliferation, while the 
relationship of other genes identified as upregulated here to decreased B cell proliferation is 
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absent from the literature. It should be considered, however, that increased translation does 
not always coincide with increased transcription. Furthermore, protein expression does not 
assure functionality. While the genes discussed here may be upregulated in Fli -I-deficient 
animals, Fli-I may control expression of posttranslational modification machinery or 
activating enzymes which were not investigated here. The observed downregulation of the 
NF AT gene may also provide a potential mechanism which drives decreased proliferation 
in Fli-I-deficient B cells. As a known activator of c-myc and BAFF, reduced NFAT 
expression in Fli-I-deficient B cells may contribute to their reduced proliferative capacity. 
Investigation of factors regulating NF AT expression, and the role ofNF AT-regulated genes 
in B cell proliferation would provide an interesting segue to future studies of the role of Fli-





Fli-l is overexpressed in lymphocytes of SLE patients as well as murine models of the 
disease (196). Transgenic overexpression ofFli-l in normal mice leads to SLE-like disease 
(195). Reduction of Fli-l expression in the MRLI/pr mouse model of SLE results in 
decreased immunoglobulin production, proteinuria, and renal pathology; and increased 
survival (197). These findings suggest that Fli-1 activity may be a central contributor to 
SLE pathogenesis. Investigation of this role and discovery of Fli-l target genes may 
provide novel therapeutic targets. 
Transgenic mice that overexpress Fli -1 exhibit innate B cell hyperplasia and 
exaggerated in vitro proliferation ofB cells in response to LPS and anti-IgM (195). Also, 
spleens from MRLllpr Fli-1+/~ mice demonstrated lower percentages of B cells and serum 
exhibited reduced immunoglobulin concentration (197). From this data it was 
hypothesized that Fli-1 deficiency may impair B cell proliferation. Additionally, it was 
predicted that Fli-l activity is integral to the process in normal immunity, outside the 
context of SLE. Because overexpression of Fli-l preceded the manifestation of disease in 
Fli-l transgenic mice, observing effects of Fli-l deficiency early in the progression of 
MRL/lpr disease was anticipated (195). 
Effects of Fli-l deficiency on B cell proliferation was evaluated in three models - Fli-
1+1- MRLI/pr, Fli-1+1- C57BL/6, and Fli_ltlCTNI1CTA C57BL/6 mice. Proliferative responses 
of naIve B cells from Fli-l-deficient mice to anti-IgM, a combination of PMA and 
ionomycin, CpG DNA, or LPS were significantly reduced compared to those of Fli-1-wild-
type mice of similar strain (Figures 5-7). Proliferation initiated by these mitogens, if not by 
all means of initiation, is affected, suggesting that Fli-l regulates B cell genes which 
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directly or indirectly influence proliferation. Proliferation of B cells from Fli-l+l- and Fli-
1 ~CTAldCTA C57BL/6 mice demonstrated impairment similar to that of B cells from Fli-l+l-
MRLllpr mice, indicating Fli-l participates in B cell proliferation under normal 
circumstances (Figures 6 and 7). More statistically significant differences in proliferation 
were observed when comparing Fli_ldCTAldCTA to wild-type C57BL/6 mice than when 
comparing Fli-l+l- to wild-type C57BL/6 mice (Figures 6 and 7). As the mutant Fli-l 
retains ability to bind DNA, it is assumed to bind the majority of available Fli-l binding 
sites. In the Fli-l-heterozygous model, however, limited availability of Fli-l protein may 
allow these sites to be occupied and activated by other ETS factors, such as Erg-3. This 
compensation for Fli-l deficiency may explain why fewer statistically significant 
differences in B cell proliferation were observed in Fli-l+l- C57BL/6 mice than in Fli-
l~cTNdcTA C57BL/6 mice compared to Fli-l+l+ C57BL/6 mice. The effect of Fli-l 
deficiency on B cell proliferation appeared to be slightly accentuated in MRLllpr mice, 
perhaps suggesting that aspects of SLE contribute to this effect. Differing genetic 
background or the lack of functional Fas receptor on MRL/(pr B cells may also influence 
the extent of the effects of Fli-l deficiency. 
B cell proliferation was evaluated in each model of Fli-l-deficiency when they were 6, 
12, and 20 weeks old - ages which correspond to various stages ofMRLllpr disease (121, 
260). Proliferative responses of Fli-I-deficient MRLllpr B cells were significantly reduced 
compared to wild-type B cell responses beginning at the pre-disease stage at 6 weeks of age 
(Figure 5). Given the development of SLE-like disease in Fli-I-overexpressing transgenic 
mice, the observed impact of Fli-l deficiency prior to disease onset suggests that abnormal 
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expression of Fli-1 is likely a contributing factor to causal events, rather than a 
consequence of disease. 
As a transcription factor, Fli-1 is able to regulate expression of multiple proteins. 
Altered expression of mitogen receptors corresponding to the mitogens used to evaluate 
proliferation was also investigated as a mechanism behind the decreased B cell 
proliferation associated with Fli-1 deficiency. A higher proportion of B cells expressing 
one of these receptors, the CpG DNA-binding TLR9, is found in SLE patients with active, 
versus remissive, disease (267). Expression of TLR9 also correlates with levels of anti-
dsDNA. It was therefore hypothesized that Fli-1 deficiency results in decreased or 
incomplete expression of these receptors. Surface expression ofBCR components IgM and 
Iga, TLR4, and TLR9, and intracellular expression of TLR9 was only slightly and 
inconsistently reduced in naIve B cells of Fli-1-deficient mice compared to Fli-l-wild-type 
mice of similar strain (Figures 9-14). Because Iga is known to be regulated by Fli-1, a 
more impressive reduction of Iga expression was expected (169). As BCR expression is 
essential to B cell development and survival, expression of Iga may not be sensitive to the 
level to which Fli-1 activity is decreased in our models. This may be true not only for Iga, 
but also for the other receptors, either because there is enough residual Fli-1 activity for 
near normal expression, or because Fli-1 plays a minor or nonessential role in regulating 
expression. Additionally, differential expression of a particular receptor did not always 
coincide with differential B cell proliferation response to the corresponding mitogen. It is 
thus unlikely that reduced expression of mitogen receptors is the mechanism driving the 
large differences in B cell proliferation observed. However, as with B cell proliferation, 
differences in mitogen receptor expression, when present, were more appreciable in 
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MRL/lpr mice than in C57BL/6 mice. As discussed earlier, genetic differences, lack of 
Fas, or others aspects of the SLE phenotype may accentuate the effects ofFli-l deficiency. 
Significantly reduced proliferative responses to all mitogens tested, including PMAIion 
which bypass interaction with cell surface receptors, suggests that mUltiple pathways are 
affected by Fli-l deficiency, and therefore the mechanism of the effect is likely a 
component common to all affected pathways. Minimal decreases in mitogen receptor 
expression on Fli-l-deficient cells also suggest that more profound effects of Fli-l 
deficiency may be found downstream. From these clues, the hypothesis that expression of 
signaling and effector proteins common to both TLR and BCR pathways is limited as a 
result of Fli-l deficiency was developed. Transcript expression of several TLR and BCR 
signaling-related genes was evaluated in MRL//pr Fli-l+l+ versus Fli-l+l- B cells. IL 12a, 
1NF~, and MPPI transcripts were upregulated in unstimulated Fli-l-deficient cells (Table 
5). MPP 1 and TLR9 transcripts were upregulated and NF A T transcripts were 
downregulated in stimulated Fli-l-deficient B cells (Table 5). 
As Fli-l is generally recognized as a transcription activator, it was unexpected to find 
upregulation of genes in Fli-l deficient cells. There are, however, a number of published 
examples of Fli-l acting as a repressor of genes including those that code for collagen type 
1 and retinoic acid receptor (150, 313). Fli-l itself may not interact with upregulated genes 
identified here, but perhaps activates expression of a repressor that inhibits their 
transcription. 
IL 12a upregulation may have a protective effect as transcript levels are below normal in 
SLE PMBC (295). Also, treatment of SLE PMBC and MRLI/pr mice with IL12 reduced 
anti-dsDNA production (296, 297). In treated mice, lymphadenopathy, splenomegaly, 
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proteinwia, and glomerulonephritis are also alleviated (298). These effects oflL12 on SLE 
parameters may contribute to the overall phenotype of Fli-l+l- MRLllpr mice. 
Upregulation of IL12 may also contribute to the effect of Fli-l deficiency on B cell 
proliferation, as IL 12 treatment reduces proliferation and tumorgenicity of malignant B 
cells in which IL12 receptor expression is induced (299). 
TNF~ upregulation may combat the overproduction of immunoglobulin in MRLllpr 
disease, as high levels of TNF~ have been observed in PBMe cultures from 
hypogammaglobulinemic children and reduction of TNF~ results in increased 
immunoglobulin production (302). Decreased immunoglobulin production has previously 
been determined in Fli-l+l- MRLllpr sera, but TNF~ levels remain unknown. Low 
production of TNF~ was associated with SLE and lupus nephritis in a Korean population 
(303). The relationship between elevated TNF~ transcripts and reduced B cell proliferation 
in Fli-l-deficient B cells requires further investigation, as literature regarding this cytokine 
and its effect on proliferation are conflicting. 
Given the role of MPP1 in mitosis, and its downregulation in Fli-l siRNA-treated 
endothelial cells, the significance of mild upregulation of MPP 1 in Fli-l+l- MRLllpr B cells 
is not clear. As are all transcription factors, Fli-l is subject to cell-specific pressures, and 
may not have a primary role in regulation of this protein in B cells. Intuitively, increased 
proliferation would be expected from cells expressing increased MPP 1. However, the 
upregulation of the MPP1 protein remains to be confirmed in MRLllpr Fli-l+l- B cells. 
Also, Fli-l deficiency may result in downregulation of another pro-proliferation protein, or 
upregulation of an antiproliferation protein, for which upregulation of MPPI cannot 
compensate. 
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Though the mechanism is unknown, absence of TLR9 in lupus-prone mice exacerbates 
disease, suggesting that upregulation of TLR9 is protective (97). While transcripts were 
upregulated in Fli-1-deficient MRLllpr B cells, assessment of receptor expression did not 
reflect this upregulation. Perhaps an alternative method of measuring TLR9 protein 
expression is needed to accurately address the question of the relationship of Fli-1 with 
TLR9, and whether this relationship influences B cell proliferation. 
Because NF A T expression is known to be induced in stimulated B cells and has an 
established role in lymphocyte proliferation, the finding of decreased NF AT transcripts in 
Fli-1-deficient B cells is most interesting (Table 5) (308-310). As a known regulator of c-
myc and BAFF, decreased NFAT expression could directly result in decreased proliferation 
(311, 312). In addition, NF A T is known to activate expression of C023, the IgE Fe 
receptor (314). The soluble form of this receptor is elevated in SLE and B-chronic 
lymphocytic leukemia (B-CLL) patient serum and enhances immunoglobulin production 
(315-317). Interaction of soluble C023 with its receptors stimulates a growth response 
(318). Selective increase of surface C023 prompts resting B-CLL cells to proceed through 
G 1 and S phase of the cell cycle (319). Blockade of CD23 ligation by anti-CD23 
monoclonal antibodies inhibits proliferation of Epstein-Barr virus (EBV)-transformed B 
cells (320). Interestingly, B220+ cells from Fli_lI:!.CTAI !J.CTA C57BL/6 mice demonstrated 
reduced surface C023 expression (unpublished data). Confirmation that NF AT expression 
is reduced in these mice may clarify the mechanism by which Fli-1 deficiency diminishes 
B cell proliferation. 
The results of the studies presented here clearly demonstrate that Fli-l deficiency affects 
B cell proliferative responses to mitogens, independent of BCR and TLR expression. 
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While this investigation failed to find BeR or TLR signaling and effector proteins 
differentially expressed as a result of Fli-1 deficiency, it should be considered that the 
genes evaluated here are not an exhaustive representation of proteins involved in these 
pathways. However, the upregulation of IL12a and downregulation of NFAT transcripts 
are prospective points from which to continue exploration of the relationship between Fli-1, 
B cell proliferation, and SLE. 
Future Directions 
These studies have resolved a very small portion of the very large SLE puzzle; and 
further research is needed in order to attain the ultimate goal of developing more effective 
treatments and improving the quality of life for SLE patients. 
Though IL12a transcripts expression was upregulated in Fli-1-deficient B cells, a 
correlative upregulation ofIL12 p35 protein must be determined. The ELISA method used 
here was not sensitive enough to detect IL 12 in the serum. An alternative detection method 
to consider may be a commercially available fluorescing microsphere immunoassay system 
(321). Also, the protocol used for collection of serum may need to be optimized (i.e. 
reduced clotting time, temperature during clotting, etc.) with IL 12 analysis in mind. 
Whether IL 12 has an inhibitory effect on nonmalignant B cell proliferation could be 
determined by addition of IL 12 to actively proliferating B cell cultures and subsequent 
evaluation of tritiated thymidine uptake. IL12 knockout mice are available, and may be 
useful for establishing the role of IL12 in B cell proliferation. If bred to the MRLllpr 
background, the significance of this role in SLE may also be investigated. As previously 
mentioned, IL12-expressing plasmids have been used to treat MRLllpr disease. IL12 
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therapy has shown moderate success in treatment of refractory lymphomas, but performed 
poorly as a treatment for chronic hepatitis C (322, 323). 
Though NF AT transcript expression was downregulated in Fli-I-deficient B cells, a 
correlative downregulation ofNFAT protein expression must be determined. Western blot 
of whole B cell lysate would address this question. Furthermore, examination of 
cytoplasmic and nuclear extracts, before and after mitogen stimulation, would determine 
whether NF A T protein is able to translocate in a Fli -I-deficient environment. Both 
polyclonal and monoclonal antibodies against NF A Tc I are commercially available (324). 
Decreased NF A T expression may correspond to decreased expression of its target 
genes. As previously discussed, c-myc and BAFF are NF AT targets of interest because of 
their known roles in B cell proliferation. BAFF-targeted therapy, in the form of a 
monoclonal antibody which neutralizes BAFF, is currently in clinical trials (325). C-myc 
may be a promising target for therapy, as pharmacological inhibition of c-myc inhibits 
proliferation of human cancer cells lines (326, 327). 
As mentioned previously, the models used here to study the role of Fli-I in B cell 
activity and SLE could be improved, and a conditional Fli-I knockout is currently being 
developed. Breeding of this knockout to a transgenic mouse whose Cre expression is 
driven by a B cell-specific promoter would provide an even clearer picture Fli-I's role in 
this cell type. Use of RNAi to knock down Fli-I expression in B cell culture was 
successful, but poor viability prevented adequate assessment of effects on proliferation. An 
electroporation technique was chosen to administer the RNAi for its efficiency of 
transfection, but a less damaging method may prove more successful. 
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While the PCR array employed here allowed evaluation of the expression of many key 
TLR- and BCR-signaling and effector proteins, there are many, known and unknown, that 
remain to be evaluated. A broader approach, such as a traditional microarray, would 
undoubtedly provide many more candidate genes to be considered. Alternatively, the 
effect of Fli -1 deficiency on proliferation may be at a more basic level than mitogen 
receptor signaling. Another focused array, restricted to mitotic genes could provide a fresh 
perspective. 
Discovery of the Fli-l target genes mediating its effect on B cell proliferation, and 
evaluation of those genes as potential therapeutic targets, may be the key to controlling 
SLE-related B cell hyperactivity. 
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